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SHORT SUMMARY 
Short Summary 
In this thesis in vitro skin models and methods were established to investigate the follicular uptake of 
nanoparticles (NP), especially quantitatively to estimate their potential for the transfollicular vaccination 
approach. To figure the amount of NP that can be deposited into the hair follicles a method was 
developed to quantify the follicular uptake of NPs. Comparing the results found in vitro in the pig ear 
model with the situation in vivo in human forearms an excellent in vitro in vivo correlation between both 
models was demonstrated, supporting the pig ear as surrogate for the situation in vivo.  
To optimize the penetration efficiency of nanoparticles surface modifications were investigated as well 
as application techniques. The presence of different phospholipid coatings on the surface of poly(lactide-
co-glycolide) (PLGA) NPs modulated the quantity of their penetration into the hair follicles. Massage is 
known to enhance the follicular penetration depth of applied NPs. However it was observed that 
massage cannot enhance the amount of NPs that penetrate the hair follicle. 
In a proof of concept study, PLGA and chitosan-PLGA NPs were prepared with ovalbumin (OVA) as model 
antigen. In a cell culture assay CD4+ and CD8+ T-cells were stimulated by encapsulated OVA to a larger 
extent than by OVA in solution. An adoptive transfer experiment in mice confirmed the possibility of 
transfollicular vaccination without previous treatment of the skin.    
Kurzzusammenfassung 
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KURZZUSAMMENFASSUNG 
Kurzzusammenfassung 
In dieser Arbeit wurden in vitro Hautmodelle und Methoden zur Untersuchung, insbesondere der 
quantitativen, follikulären Aufnahme von Nanopartikeln (NP) entwickelt um deren Eignung für die 
transfollikuläre Vakzinierung zu untersuchen.  
Es wurde eine Quantifikationsmethode entwickelt, um die Menge an NP zu bestimmen, die im 
Haarfollikel deponiert wird. Zwischen den Ergebnissen mit dem Schweineohr als in vitro-Modell und dem 
Unterarm von Probanden in vivo besteht eine hervorragende in vitro–in vivo-Korrelation, welche die 
Eignung des Schweineohrs als Surrogat für die Situation in vivo belegt.  
Um die Effektivität der Penetration in die Haarfollikel zu optimieren, wurde untersucht welchen Einfluss 
Oberflächenmodifikationen am NP und die Anwendung spezieller Auftragetechniken haben. So sind 
Überzüge aus verschiedenen Phospholipiden in der Lage das Ausmaß der Penetration von NP aus 
Polylactid-co-Glycolid (PLGA) zu modulieren. Es ist bekannt, dass NP tiefer in die Haarfollikel eindringen, 
wenn sie in die Haut einmassiert wurden. Jedoch vermag Massage nicht die Menge im Haarfollikel zu 
steigern. 
Für eine Machbarkeitsstudie wurden PLGA und Chitosan-PLGA NP mit Ovalbumin als Modellantigen 
beladen hergestellt. Im Zellkulturversuch wurden CD4+- und CD8+-T-Zellen durch Ovalbumin beladenen 
Partikel stärker stimuliert als durch eine Ovalbumin-Lösung. Beim adoptiven Zelltransfer im Mausmodel 
konnte bestätigt werden, dass die transfollikuläre Vakzinierung ohne Vorbehandlung der Haut möglich 
ist. 
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1.1. INTRODUCTION  
 
Infectious diseases impose a serious threat to public health worldwide. Among the strategies to fight 
infections only vaccination has the potential to eradicate the disease (the World Health Organization, 
WHO, certified the eradication of smallpox in 1979). New, safe, efficient, and cheap vaccination 
strategies are desperately needed to meet the needs of a growing population in developing countries as 
well as the challenges of fast spreading infectious diseases due to global traffic (e.g. 2009 swine flu 
pandemics).  
Particle based vaccine formulations for trans cutaneous immunization (TCI) address several key issues in 
vaccination today. First of all TCI has been shown to induce superior immune responses as compared to 
systemic vaccines and to hold the potential to convey mucosal immunity. This is highly desirable to 
prevent microbial pathogens from entering the body through mucosal surfaces and thus block disease at 
a very early stage. This will also help to reduce the risk of horizontal transmission from infected 
individuals to susceptible hosts.  
Many of the current strategies for TCI (e.g. micro-needles, Gene gun, PowderJect, skin abrasion), reduce 
the protective stratum corneum (SC) barrier for a significant time to facilitate the absorption of the 
vaccine. This makes them suboptimal for mass vaccination campaigns under critical hygienic conditions. 
Particle based formulations are an interesting alternative to this. Needle free strategies are at the 
forefront to combat vaccination-related transmitted diseases due to sharing of needles or needle stick 
accidents.  
Over the past decade, particulate carriers have emerged as an attractive delivery strategy for antigens 
and adjuvants. Particle based formulations combine several desirable aspects which make them very 
attractive for antigen encapsulation. Vaccine antigens are often difficult biological entities, including 
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DNA, peptides, proteins, attenuated viruses, microorganism fragments. (Nano)encapsulation can 
improve the stability, facilitate absorption and also increase antigenicity by mimicking the size of 
microorganisms.  
The co-delivery of adjuvants is tantamount to increase the immunogenicity of the antigen and may allow 
a reduction of the antigen dose. In the context of vaccination so-called dose sparing allows reaching 
more people when limited amount of vaccine antigen is available such as in global pandemics. 
Furthermore, vaccines with higher efficiency are also needed to enable protection of immunosuppressed 
and elderly patients. Importantly, by choosing the right adjuvant it is possible to polarize the immune 
response in a predetermined direction and convey mucosal immunity. 
However, until now TCI using particle based vaccine formulations has made no impact on medical 
practice. One of the main difficulties is that nanoparticles (NPs) cannot penetrate the skin to an extent 
that would allow the application of the required dose of antigen. This is due to the formidable SC barrier, 
the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude 
of strategies are currently under investigation to overcome these issues. We highlight selected methods 
presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC 
barrier and the combination of particle based vaccines with adjuvants discussing their advantages and 
shortcomings. Some of these are currently at an experimental state while others are already in clinical 
testing. All methods have been shown to be capable of transcutaneous antigen delivery. 
Introduction 
1 
 
1.3 ABSORPTION ROUTES TO NP APPLIED TO THE SKIN 
 
One of the main challenges in TCI is that the vaccine antigens need to overcome the SC barrier in order 
to reach the Langerhans cells (LCs) in the epidermis which act as antigen presenting cells (APCs). Intact 
human skin is widely impermeable to solid NPs and microparticles (MPs). Ultra-flexible liposomes are an 
exception to this rule. Due to the addition of edge activators such as surfactants and/or ethanol they are 
able to change shape and squeeze through the lipid channels of the SC, supposedly following an osmotic 
gradient. [1, 2] Ultra-flexible liposomes have been used foremost for encapsulating protein antigens. [3, 
4] By including positively charged lipids in the formulation they become amenable to complexing 
nucleotide based drugs and thus may be an alternative for DNA vaccination. [5-7] For a more extensive 
overview the reader is referred to some recent reviews. [8, 9] Furthermore, ultra-small NPs with sizes 
less than 10 nm can enter the SC to a low and highly variable extent. [10] The toxicity and lack of 
biodegradability of quantum dots, metal or metal oxide NPs notwithstanding, ultra-small NPs are not 
suitable for drug delivery and vaccination purposes due to the extremely small amount of drug or 
antigen which can be loaded onto these particles. Also due to their low and variable degree of 
penetration such formulations would probably require some active means of penetration enhancement 
to enable delivery of a suitable dose.  
 
1.4 NP FOR TRANSCUTANEOUS VACCINATION 
 
Polymeric NPs as well as lipid carriers which are often in the size range of a few 100 nm are especially 
interesting delivery systems for the purpose of TCI. Nonflexible NPs which are applied onto the skin 
migrate into the hair follicle openings by a size-selective mechanism (Figure 1a). [11] The hair follicle is a 
promising target for TCI without compromising the skin barrier. [12] Interestingly, the trans-follicular 
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route is a common pathway for the invasion of allergens such as pollen grains. [13] First evidence for the 
importance of the transfollicular route for transcutaneous vaccine delivery came from differences 
observed between hairy and nude mice. [14] At least for DNA vaccines the hair cycle state also seems to 
determine the successful transfection. [15] Inside the hair follicles antigen uptake by the rich pool of 
peri-follicular APCs is facilitated due to the absence of a SC barrier in the lower follicular orifice. [16] 
Therefore this delivery strategy does not require application of any further measures which would 
reduce the skin barrier. It seems that transfollicular delivery elicits a CD8+ biased response which is 
recommendable for combating intracellular microbes and developing vaccines against cancer and virus 
infections. [17] We showed that transfollicular delivery of the nano-encapsulated model antigen 
ovalbumin (OVA) elicited similar proliferation of OVA specific CD4+ T cells as an i.m. injection of the same 
dose of soluble antigen in an adoptive transfer model. [12] Nano-encapsulation into polymeric NPs 
improved the delivery of OVA into the hair follicles on excised pig ears by a factor of 2.5-3 compared to 
OVA in solution and protected OVA from cleavage or aggregation so that it maintained its biological 
activity to a high degree during storage and shipping. [12] As an important outcome of the study we 
observed in vitro as well as in vivo an intrinsic adjuvanticity of the NPs which was also influenced by the 
polymer material used. [12] The effect can probably be enhanced and directed by the combination or co-
encapsulation of adjuvants into the formulation. As hair follicles cover only 0.1% of the skin surface 
trans-follicular delivery has long been discussed to be negligible. It was demonstrated however that the 
capacity of hair follicles is similar to that of the SC. [18] Lademann et al showed that NPs penetrated 
more efficient into the hair follicles than solutions and form a depot in the follicle that persists for more 
than one week. [19] Still a big issue with transfollicular application is the loss of formulation on the skin 
surface. Consequently a higher amount of vaccine would be required to achieve delivery of the required 
dose, which will need to be optimized in the future to make transfollicular vaccination a real alternative.  
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Fig.1:  Schematic representation of methods to enable or facilitate TCI: a) transfollicular 
delivery, b) mechanical dermabrasion, c) jet injection of liquids or powders, d) microneedles (Images are 
not drawn to scale) 
  
1.5 FACILITATED ABSORPTION METHODS 
 
Particle based vaccines benefit from any form of skin pre-treatment which reduces or removes the SC or 
any mechanical or electrical application method which transfers them into the epidermis by force (for 
review see also [20]). Occlusion or chemical penetration enhancers, while enhancing permeation of 
molecules by several folds due to influencing molecular partition and/or diffusion coefficients, have very 
little effect on the permeability of particles. [21] Apart from facilitating invasion the barrier disruption 
additionally causes a non-specific immunostimulation. [22] Often these facilitating methods require 
special devices. Important points to consider in this context include (i) cost for devices, (ii) ease and 
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reproducibility of use also by non-trained personnel (e.g. in a pandemic or for mass vaccination in 
developmental countries lacking medical infrastructure), (iii) severity and area of barrier disruption, time 
scale of barrier recovery which are connected to the risk of invasion of pathogens through the superficial 
wound. The severity of these issues varies depending on the type of vaccination which is aspired. 
Naturally the tendency to tolerate risk is higher with therapeutic vaccines than with prophylactic 
immunizations.  
For example mechanical abrasion of the SC across a large area may be acceptable to improve the 
permeability of an HIV vaccine. In the DermaVir patch plasmid DNA encoding for 15 HIV antigens is 
complexed with mannosylated positively charged polyethylene imine to form particles with sizes of 80-
400 nm. [23] Mannosylation in this case facilitates the uptake of the particles by APCs. The patch is 
applied onto skin sites (2-8 areas 80 cm² each on the back and the thighs) which are previously being 
abraded with a DermaPrep medical sponge (Figure 1b). [24, 25] In phase II clinical trials the patch was 
applied to HIV infected individuals on combination antiretroviral therapy (cART). [24, 25] The treatment 
was well tolerated also in a dose escalation study; mostly side effects were limited to mild local irritation. 
[24, 25] The vaccination increased CD-8+ cell counts and may enable intermission of cART. [24]  
Devices such as jet-injectors (Figure 1c) or gene guns may relatively easily be compatible with particle 
based vaccine formulations. The principle relies on the generation of a jet of liquid or powder 
formulation which is propelled into the skin with great force. Dry formulations have considerable 
stability advantages. Depending on volume and injection depth a small amount of pain or bleeding and a 
relatively strong local inflammation may occur. [26] Immunogenicity is reported to be higher or equal to 
classic vaccine application. [26, 27] The history of using jet-injectors for vaccination goes back to the 
1950s. [28] Problems with cases of hepatitis B which were transmitted person-to-person by multi-dose 
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injectors were overcome by next generation devices which may either be prefilled for single use or come 
with exchangeable cartridges. [29]  
As a third technology with great potential to facilitate the absorption of NPs microneedles (Figure 1d), 
either solid, hollow, or biodegradable, should be mentioned. They can be used for pretreatment (e.g. 
Derma Roller) or as a leave on patch which also delivers the formulation. Although not needle-free they 
reduce sharps associated issues. In contrast to intradermal injections (including the prefilled syringe 
system BD soluvia which is approved in Europe for influenza vaccination) microneedles only reach the 
epidermis, stay above the dermal nerve endings and avoid pain. The particles can indeed be integrated in 
the microneedle arrays. DeMuth et al. constructed a system made from biodegradable antigen loaded 
MPs. [30] MPs made of poly(lactide-co-glycolide) (PLGA) were embedded in water soluble poly(acrylic 
acid) (PAA) which actually forms the microneedles. [30] Upon insertion into the skin, PAA dissolves; the 
microneedles themselves disintegrate and leave a depot of MPs providing controlled release of the 
antigen. [30] This design may enable separate delivery of a fast (from the matrix) and a slowly available 
dose (from the MPs, in mice MP-associated fluorescence was demonstrated up to 10 days after 
microneedle insertion at the site of injection). [30] Likewise the system could be advanced to deliver 
initial and booster doses of the vaccine in a single application.  
 
1.6 INTRINSIC ADJUVANT EFFECT - INFLUENCE OF PARTICLE PROPERTIES 
 
While for most applications NPs should be inert, that means that complement activation is not desirable, 
an immuno-stimulatory effect of the nano-formulation may be a benefit for vaccination purposes. 
Various properties such as size, surface charge and material properties play a vital role in shaping an 
immune response. A wide variety of particulate systems, including liposomes, virosomes, nanocomplexes 
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and polymer based carriers are being investigated, all showing a different immunological outcome. For 
example, a particle based vaccine formulation may be capable of provoking a strong humoral response 
but fail to generate cellular responses. This might be due to different particle properties.  
It is widely accepted that particle based vaccine delivery systems are more immunogenic than soluble 
antigen as particulate system mimic the size and structure of a pathogen. Among others this is due to the 
enhanced uptake by APCs. Carrier size also plays an important role in determining the type of response 
induced. [31] Recently, Mottram et al. showed that small differences in particle size (20-200 nm) 
influence the cytokine balance after a single immunization, showing that particle size in the range of 40-
49 nm induces type 1 (cellular) responses and larger particles with 93-123 nm inducing type 2 (humoral) 
responses. [32] These findings are especially noteworthy while considering strategies of immunization 
against viruses where cellular responses are required.  
Surface charge of the particles is another vital property which not only determines the stability of 
particles but plays an important role in contributing the immuno-regulatory effect of the particulate 
systems. With respect to TCI, Rancan et al. showed that positively charged particulate systems seem to 
be taken up better by LCs due to electrostatic interactions with cell membrane eventually favouring their 
internalization. [33] Moreover, Ma et al. showed even the appropriate surface charge density is crucial to 
have an effective and efficacious immune-regulatory effect. [34]  
Finally, particle material may influence immunogenicity. The main function of a material is to stabilize 
the antigen by protecting it from the surrounding biological conditions, to slow down the clearance of 
antigens and to enhance delivery to APCs with design constraints such as biodegradability and 
biocompatibility. One strategy is to use materials extracted from microbial (e.g. total polar lipid extract 
from archae bacteria, or poly-γ-glutamic acid [35, 36]) to formulate particulate carriers. Interestingly, the 
materials themselves do not show adjuvant properties when delivered as solution but when formulated 
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as particulate carrier they up-regulated cytokine responses and MHC molecules, suggesting that 
particulate formation is necessary for the interaction between materials and certain surface molecule on 
APCs. [35, 36] 
 
1.7 COUPLING NP WITH ADJUVANTS 
 
Adjuvants are commonly added to vaccine formulations to enhance immunogenicity of poorly 
immunogenic antigens such as subunit vaccines or to shape the type of immune response, e.g. to 
increase cellular responses. For the same reasons particulate vaccine formulations may be combined 
with adjuvants. A variety of adjuvants are being used in clinical testing, marketed formulations as well as 
in research settings with different mode of actions. An important consideration is the risk of side effects 
by adjuvants. This is especially true for prophylactic vaccines which are given to healthy people and 
therefore have to fulfill the strongest safety criteria. For example cholera toxin and E. coli heat labile 
toxine (LT) are both very effective adjuvants for TCI and are very effective in humans. [37] Nonetheless 
considering the application of LT as patch against travellers’ diarrhea even the appearance of skin rashes 
and discoloration at the patch site may lead to the termination in a late clinical phase. At present, the 
choice of adjuvant is a compromise between necessity for adjuvanticity and minimal level of side effects. 
[38] Nevertheless, combination of adjuvant, antigen and particulate carrier may reduce the dose of 
antigen as well as adjuvant required in the formulation and consequently minimize the risk of side 
effects of novel adjuvant candidates for prophylactic vaccines. [39, 40] Adjuvants may either be (i) simply 
co-administered with encapsulated antigen, (ii) encapsulated in separate particles or (iii) co-
encapsulated with the antigen in the same particle. Alternatively the particle surface may be decorated 
with the adjuvant by physical or chemical association (Fig.2.).  
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Fig.2:  Combinations of antigen and adjuvant in a particulate carrier: a) adjuvants are co-
administered with the encapsulated antigen, b) antigen and adjuvant are encapsulated in separate 
particles, c) antigen and adjuvant are co-encapsulated in same particle, d) the particle surface is 
decorated with the antigen and/or the adjuvant by physical or chemical association. 
 
 
 
 
 
Recently, Bershteyn et al. showed that co-delivery of antigen with an adjuvant decorated on the surface 
of a particle generates humoral as well as cellular immune responses at ultra-low doses (at nanogram 
levels) of antigen and adjuvant. [41] In the same study, the authors have shown that co-loading of 
antigen and adjuvant in the same particle after a single immunization was significantly advantageous 
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compared to antigen and adjuvant delivered on separate particles. But this advantage was lost after a 
boost immunization, suggesting that after boosting it does no longer matter whether antigen and 
adjuvant were on the same or separate particles. However, conflicting results exist in literature, whether 
it is beneficial to co-encapsulate adjuvant and antigen in the same particles or admix the adjuvant just 
prior to immunization (either in solution or separately encapsulated) in order to generate long lasting 
immune responses. [42, 43]  
Future studies also need to clarify which type of association between adjuvant and particle should be 
preferred. Conceivably this may depend on the type of adjuvant used. For example, an adjuvant which 
has receptors expressed on the surface of APCs (e.g. some sugars such as mannose) will probably benefit 
from being displayed on the particle surface. In contrast, encapsulation of intracellularly processed 
adjuvants will possibly generate a more robust immune response due to enhanced uptake by APCs and 
intracellular delivery compared to administration as solution. [44] Overall, combining adjuvant and 
antigen in particulate carriers either by (co-)encapsulation or admixing is an attractive approach to 
improve the efficacy of vaccines and reduce the cost of vaccination.  
 
1.8 CONCLUSION 
 
Altogether particle based vaccines hold great promise for TCI. However, their successful delivery is not 
without challenge. A product which makes it to the market probably needs to combine particles, antigen, 
adjuvant, and a device to achieve both a sufficient immunogenicity and sufficient permeation. This 
naturally increases the regulatory hurdles. At the same time production costs of the product should still 
be low to extend its affordability beyond the industrialized world. Some of the solutions presented in this 
overview raise hopes that this may indeed be achievable in the future. 
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2. AIM OF THE THESIS 
Aim of the thesis 
The aim of the thesis was to establish in vitro skin models and methods to investigate the uptake of 
nanoparticles into hair follicles, especially quantitatively to estimate the potential of this type of carriers 
for transfollicular vaccination.  
The following strategy has been used to achieve this objective:  
1. Development of a method to quantify the uptake of nanoparticles into hair follicles 
2. Verification of the pig ear skin model for quantitative evaluation of nanoparticle uptake into hair 
follicles in comparison with the situation in vivo in humans 
3. Determination of the influence of nanoparticle material on follicular penetration  
4. Determination of the influence of application techniques on the extent of nanoparticle 
penetration  into hair follicles 
5. Proof of concept studies to evaluate if antigen loaded nanoparticles can induce an immune 
response via the transfollicular route when applied onto the intact skin barrier 
Based on the differential stripping technique a fully quantitative method was developed to monitor the 
fate of particles applied onto the skin surface (Chapter 3).  
The suitability of the pig ear skin model as substitute for human forearm as potential application site was 
verified in a comparative in vitro-in vivo study (Chapter 3).  
The influence of nanoparticle material on hair follicular uptake was investigated with nanoparticles 
based on PLGA carrying different surface modifications with varying charge and lipophilicity in pig ear as 
well as in human volunteers (Chapter 3). 
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As the amount of deliverable drug is very limited, methods to enhance the uptake of nanoparticles into 
hair follicles are highly relevant. A well-known phenomenon in hair follicle targeting described in the 
literature is the penetration depth enhancing effect of massage. To clarify if this effect is not only 
qualitative but also quantitative, the uptake of fluorescently labeled PLGA nanoparticles applied with and 
without massage was investigated (Chapter 4).  
Moreover nanoparticle-based formulations are known to penetrate the hair follicle deeper than liquid 
formulations. The extent of the superiority of nanoparticles compared to solutions was determined as 
well (Chapter 5).  
For prove of concept transfollicular vaccination across the intact skin was investigated using OVA loaded 
PLGA and Chit.-PLGA nanoparticles. Stability, biological activity and immunogenicity of the model antigen 
OVA were assessed. An adoptive transfer model in mice should clarify if a successful antigen delivery and 
immunization via the transfollicular route without pretreatment of the skin is possible.  
 
The thesis will be organized in three chapters entitled: 
Chapter 3: “Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm” 
Chapter 4: “Influence of application technique on the uptake of nanoparticles into the hair follicle” 
Chapter 5: “Non-invasive delivery of nanoparticles to hair follicles – a perspective for transcutaneous 
immunization” 
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3. QUANTIFICATION OF NANOPARTICLE UPTAKE INTO HAIR 
FOLLICLES IN PIG EAR AND HUMAN FOREARM  
 
 
Quantification of nanoparticle uptake into hair follicles 
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3.1 INTRODUCTION 
 
Recently hair follicles (HF) gained attention as an alternative pathway for dermal absorption which often 
facilitates permeation. Despite a relatively low surface coverage of ca. 0.1% [45] the HF contribute 
significantly to the absorption of small molecules, especially those with low to intermediate octanol-
water partition coefficients [46], and importantly, also to the absorption of (sub)micron particles [11]. In 
fact, for drug delivery approaches the HF represent interesting target sites. Due to the slow clearance 
rate by sebum flow and hair growth especially NP build a depot inside the HF where they are protected 
from contact with clothing and are not easily washed off [47]. Also, the SC is absent in the lower third of 
the HF which facilitates the absorption of substances. Thus transfollicular delivery has been investigated 
in the context of needle free vaccination [48], delivery strategies for macromolecules [49, 50], NP-based 
sunscreens [51], as well as for risk assessment applications [52]. Moreover, for HF related disorders such 
as alopecia [53, 54] or acne [55], the HF itself is the target site.  
To improve therapeutic drug delivery via the HF it is of interest to optimize NP in a way that achieves the 
highest possible uptake into the HF. It is well established that NP invade deeper into HF than solutions 
[56] and that invasion depth depends on particle size. From cross-sections of terminal HF on pig ear an 
optimum particle size of ca. 645 nm was identified, which seems to be independent of particle 
composition [11]. Therefore a mechanical effect for follicular entry has been postulated [11]. Besides the 
penetration depth, the amount of NP delivered into the HF is of interest as it allows for example 
comparing the efficacy of therapeutic treatments by comparing the delivered dose of an encapsulated 
active and optimizing the targeting efficiency of NP into the HF. The differential stripping technique 
should be suitable to quantify follicular uptake. This technique relies on first sampling the SC by tape 
stripping to evaluate the portion of analyte deposited on the skin surface and penetrated into the SC and 
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separately sampling the HF content by a cyanoacrylate (superglue) biopsy. Differential stripping has been 
applied before in vitro on the pig ear model as well as in human volunteers to qualitatively and semi-
quantitatively investigate follicular uptake of fluorescent solutions as well as a number of model NP or 
sunscreens [57, 58]. This was done by relating the amount of fluorescent NP recovered from the HF to 
the amount remaining on the skin surface. However, by demonstrating mass balance and coupling 
differential stripping with a sufficiently sensitive and robust analytical method (e.g. fluorescence 
spectrometry, HPLC-UV/MS, scintillation counting depending on NP cargo or label) it should be possible 
also to use the method for quantifying NP distribution after topical application, and particularly for 
quantifying NP uptake into HF. 
There are only two studies investigating the influence of particle size, surface charge, material and shape 
on the uptake across the inter-follicular epidermis. However, follicular targeting was not addressed in 
particular. Labouta et al. found greater skin penetration of gold NP with a hydrophobic surface [59]. Lee 
et al. found negatively charged gold nano rods to be superior compared to positively charged nano rods 
[60]. It is currently not known whether these results are also relevant to uptake into the HF. Furthermore 
it has been shown before that the penetration of superfine particles is quite different from NP a few 100 
nm in size or MP [61]. It is therefore uncertain whether the results for superfine particles can be 
extended to larger particles. In this study we developed a method to quantify NP uptake into HF and 
applied it in vitro in a pig ear model and in vivo in human volunteers. This method allows investigating 
the uptake of NP into HF systematically. The HF is filled with sebum, and therefore provides a mainly 
lipophilic environment [62]. Therefore we hypothesized that lipid coating may facilitate NP uptake into 
HF. To exclude size effects we used NP of similar hydrodynamic sizes (163-170 nm) but different surface 
modifications. As it is known that phospholipids (PL) are part of the sebum we investigated 
systematically quantitative HF deposition with fluorescence labeled NP based on PLGA: i) plain PLGA; ii) 
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chitosan coated PLGA (Chit.-PLGA); and iii) Chit.-PLGA coated with different phospholipids (PL) DPPC 
(100), (DPPC : Chol (85 : 15), DPPC : DOTAP (92 : 8). Differential stripping was performed including 
complete mass balance. The samples were extracted for fluorescence quantification. An effect of the PL 
coating on follicular uptake was observed as plain DPPC and DPPC : DOTAP (92 : 8) penetrated into HF to 
a higher extent than the other tested NP. The effect was observed both in vitro in a pig ear skin model as 
well as in vivo in human volunteers, although it was statistically significant only in the in vitro model. An 
excellent in vitro in vivo correlation (IVIVC, r² = 0.987) between both models was demonstrated, further 
supporting the suitability of the pig ear model as a surrogate for the in vivo situation in humans to study 
NP uptake into HF quantitatively.  
 
3.2 EXPERIMENTAL METHODS 
 
3.2.1 CHEMICALS AND METHODS 
 
We purchased PLGA (Resomer RG 50:50 H; inherent viscosity 0.31 dl/g) from Boehringer Ingelheim 
GmbH & Co. KG, Ingelheim, Germany; ultrapure chitosan chloride salt (Protasan® 8 UP CL113) from FMC 
BioPolymer AS, Oslo, Norway; polyvinyl alcohol Mowiol® 4-88 (PVA) from Kuraray Specialties Europe 
GmbH, Frankfurt, Germany; Tesa film from TESA SE, Hamburg, Germany; and nano screen-MAG NP from 
chemicell GmbH, Berlin, Germany. All other solvents and chemicals used were of the highest purity 
available. Deionized water (dd water, Milli Q Plus system, Millipore, Bedford, MA, USA) was used 
throughout.  
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3.2.2 PIG EAR SKIN AND HUMAN VOLUNTEERS 
 
Pig ears were obtained from a local abattoir from freshly slaughtered pigs removed before scalding. Only 
ears with immaculate skin surface were used. Ears were stored at 2 – 8 °C for a maximum of two days. 
Treatment occurred on the outer auricle. 
Eleven volunteers (Caucasian, five female, six male, skin type II – IV) with no history of skin disease 
participated in the study, which was approved by the “Ärztekammer des Saarlandes” ethical committee 
and in adherence with the Declaration of Helsinki Principles. All volunteers signed informed consent. 
Treatment occurred on the outer forearm due to the larger number of hair follicles compared to the 
inner forearm. Subjects were asked not to use any cosmetics on the application site on the day of the 
experiment.  
3.2.3 NANOPARTICLES 
 
For visualization nano screen-MAG nanoparticles (chemicell GmbH, Berlin, Germany) were used. The 
particles have a hydrodynamic diameter of 100 nm and are fluorescently labeled. They are composed of 
a solid magnetite core and covered with a chitosan matrix. The nano screen-MAG serve as model NP as 
they are visible on the skin by eye due to their dark brown color as well as by fluorescence and 
environmental scanning electron microscopy ESEM microscopy. 
PLGA-NP were prepared by a double emulsion method described in [48]. Chit.-PLGA NP were prepared 
by the emulsion-diffusion-evaporation technique described in [63]. For PL coating Chit.-PLGA NP were 
incubated with large, unilamellar vesicles consisting of DPPC, a mixture of DPPC : Cholesterol (85:15), or 
DPPC : DOTAP (92:8) respectively. Via ultrasonification the lipids formed self-organized PL bilayers on the 
NP surface [63]. PLGA was covalently labeled with fluoresceinamine (FITC-PLGA) according to [64] to 
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prevent the label from leaking from the NP and avoid free dye diffusion. Cleavage of FITC-PLGA by 
esterases in the skin is not relevant within the timeframe of the experiment [64].  
PLGA NP were stored as freeze-dried powder and re-suspended in dd water to obtain the desired 
concentration prior to use. Chit.-PLGA NP and PL coated Chit.-PLGA NP were stored as stable suspension 
at 4-8° C for a maximum of 14 days after manufacturing. Immediately before each experiment the 
hydrodynamic diameter, size distribution, and zeta potential were determined using a Zetasizer Nano-ZS 
(Malvern, Malvern UK).  
3.2.4 APPLICATION PROTOCOL AND SAMPLING 
 
The same standardized application and sampling protocol was used for pig ears in vitro and human 
volunteers. The ears and outer forearm was wiped with cold water, blotted dry with tissue and allowed 
to dry completely. Hairs were shortened with scissors and incubation sites of 1.767 cm2 were marked 
with water resistant marker. PLGA NP were tested on 4 ears with 2 application areas each and 6 
volunteers with 3 application sites each; plain and PL-coated Chit.-PLGA NP were tested on 3 ears with 2 
application sites each and 5 volunteers with 1 application sites each. On each ear and in each volunteer 
one additional area received blank formulation (dd water). Due to space limitations not all particles can 
be tested in the same volunteers. The results are nonetheless comparable between particles due to 
subtracting blanks obtained for each individual. 15 µl of PLGA NP suspension were applied, and 
massaged for three minutes with a gloved forefinger. Due to constraints from manufacturing the 
concentration of plain and PL coated Chit.-PLGA NP was much lower than for PLGA NP. In order to obtain 
reasonable quantification limits a higher volume of 30 µl of NP suspension was applied, and no massage 
was performed to avoid removal of formulation. Instead the suspension was carefully distributed with a 
pipette tip. The formulation remained on the skin of the volunteers for one hour without coverage. Pig 
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ears were kept in an incubator at 32° C for an equal time period. The temperature of 32° C is equivalent 
to the human skin surface temperature and is recommended for the performance of in vitro skin 
experiments [65]. Afterwards the skin distribution of the NP was analyzed by extracting the following 
sample fractions: 
(a) 10 Tape strips were taken to collect NP remaining on the skin surface. To standardize the pressure 
with which each tape was pressed onto the skin surface and to minimize the influence of furrows and 
wrinkles a roller device was used [66]. The first and second tape strips were extracted separately. 
Subsequent tape strips were extracted in pairs of two. (b) Two cyanoacrylate biopsies were performed 
putting a drop of superglue in the center of the incubation site and covering it under slight pressure with 
a tape strip. The glue was allowed to polymerize completely for at least 5 min and the tape strip was 
removed with a quick movement containing the cast of the HF including the NP. (c) For mass balance a 
punch biopsy of 4.91 cm² including the incubation site was taken from pig ear skin to sample the skin 
rest. In the volunteers the same area was swabbed with cotton soaked in ethanol instead. The solvent 
was allowed to evaporate completely before extraction. (d) Also the application devices (glove fingers for 
PLGA NP, pipette tip for PL-coated Chit.-PLGA NP) were extracted.  
3.2.5 SAMPLE EXTRACTION AND QUANTITATIVE ANALYSIS 
 
All samples were extracted in acetonitrile (ACN) : 0.1 N sodium hydroxide (NaOH) (70:30) for three hours 
under light exclusion and then centrifuged (5 min, 20 °C, 24651 g). Fluorescence intensities of all samples 
were measured (excitation λex = 490 nm, emission λem = 525 nm) in a plate-reader (TECAN infinite M200, 
Tecan GmbH, Crailsheim, Germany). For calibration, a stock suspension with known NP concentration 
(wt/V) was prepared in ACN : 0.1N NaOH (70:30), extracted for three hours and diluted with ACN : 0.1N 
NaOH to obtain standards.  
Quantification of nanoparticle uptake into hair follicles 
19 
 
3.2.6 NP VISUALIZATION ON SKIN 
 
15 µl nano screen-MAG NP suspension (0.375 mg NP) were applied onto pig ears. Incubation and 
sampling was performed as described above. Scan images of the incubation sites were taken using a 
flatbed scanner (Epson Perfection 3200 Photo, 600 dpi, 24 Bit) (i) of the incubated area, (ii) after 
performing ten tape strips, and (iii) of a non-incubated reference area. Furthermore, cyanoacrylate 
biopsies were investigated by light microscopy (Olympus BH 2, 20-fold magnification).  
Additionally, the tape strips, skin sample after tape stripping and cyanoacrylate biopsies were visualized 
by confocal microscopy (LSM 510 Meta, Carl Zeiss GmbH, Jena Germany). Auto fluorescence of the skin 
samples, tapes and cyanoacrylate was compensated by using λex = 458 nm and band pass filter 520-
555 nm. The microscopic settings were adjusted using tape strips and cyanoacrylate biopsies from a 
blank experiment as negative and a droplet of NP-suspension distributed on an objective slide as positive 
control. 
The same kind of skin samples were further imaged by environmental scanning electron microscopy 
(ESEM, Quanta 400 FEG, FEI Deutschland GmbH, Germany) in low vacuum mode at a pressure of 100 Pa 
and an acceleration voltage of E = 20 keV. A large field detector was used to image topography. A solid 
state detector was used to enhance contrast between skin, hairs and the metal core NP. Three regions of 
interest (ROI) were determined on the hair, the skin surface and near the HF orifice and x-ray spectra 
were obtained using an EDAX Genesis V 6.04 analysis system at E = 20 keV 
3.2.7 METHOD VALIDATION  
 
Lower limits of detection (LLOD) and of quantification (LLOQ) of (i) all tape strips, (ii) cyanoacrylate 
biopsies, (iii) both application devices (glove finger, pipette tip), (iv) cotton swab, and (v) skin rest were 
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calculated by averaging the fluorescence intensity obtained from blank experiments by applying dd 
water instead of NPs (in vitro: n=23, in vivo: n=11). Extreme outliers of all blank values were removed 
separately for each group (i) to (v) by applying the following protocol: Initially, the first quartile Q1 (25
th 
percentile), third quartile Q3 (75
th percentile) and interquartile range (IQR, difference between Q3 and 
Q1) were calculated. Subsequently, all data points outside the [Q1 - 3×IQR, Q3 + 3×IQR] interval were 
removed from the data sets. LLOD and LLOQ were defined as the mean fluorescence intensity plus twice 
or thrice the standard deviation of the adjusted data sets, respectively. The intra- and inter-ear variability 
was determined from blank experiments on 4 ears with 3 application sites each. For the cyanoacrylate 
biopsy, the application device, and the skin rest the intra-ear variability was calculated from the relative 
standard deviation (%SD) between all samples obtained from the same ear. The inter-ear variability was 
calculated from relative SD between all samples obtained from all 4 ears.  
3.2.8 STATISTICS 
 
Statistical testing was performed by one-way ANOVA with Holm-Sidak all pairwise multiple comparison 
procedure.  
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 NP CHARACTERIZATION 
 
The properties of the investigated NP are summarized in table 1. All NP have different compositions 
and were prepared by two different preparation techniques. Non-modified PLGA particles were 
prepared by a double emulsion method with PVA as stabilizer. Plain and PL coated chitosan 
modified PLGA NP were prepared by an emulsion-diffusion-evaporation technique. With both 
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techniques the particle size can be adjusted by using the correct conditions, e.g. stabilizer-
concentration or speed of the homogenizer.  
PLGA NP have a negative zeta potential, Chit.-PLGA and PL-coated Chit.-PLGA NP have positive zeta 
potentials of similar magnitude. We consider PL-coated NP to have more lipophilic surface properties 
than the other two, although there is to date no convenient and reliable method to quantify NP surface 
lipophilicity [67]. 
 
Table 1 Particle characterization. Mean ± SD of n = 3 individually prepared batches 
 PLGA NP Chit.-PLGA NP DPPC : Chol (85:15) 
coated Chit.-PLGA 
NP 
DPPC : DOTAP 
(92:8) coated 
Chit.-PLGA NP 
DPPC (100) 
coated Chit.-
PLGA NP 
Hydrodynamic size (nm) 162.8 ± 0.06 167.3 ± 3.0 158.9 ± 0.9 156.6 ± 1.8 169.6 ± 3.0 
PDI 0.06 ± 0.01 0.16 ± 0.03 0.10 ± 0.02 0.17 ± 0.01 0.23 ± 0.01 
Zeta potential (mV) -33.6 ± 2.5 30.0 ± 3.2 26.6 ± 0.8 27.5 ± 0.9 17.0 ± 1.4 
 
 
3.3.2 NP VISUALIZATION ON SKIN 
 
It is necessary to show that differential stripping is able to separately sample the NP from the skin 
surface including wrinkles and dermatoglyphs and the HF. Due to the size of the NP used in this study 
and their rigidity one can exclude that they enter the intact SC of human or pig skin [61].  
Figures 1a and 1d show scan and ESEM images of 100 nm fluorescently labeled nano screen-MAG on the 
skin surface of a pig ear in comparison to the surrounding non-incubated area. Nano screen-MAG were 
homogenously distributed across the incubation site (Fig.1 a). After ten tape strips the brown color 
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remained only in the orifices of the HF (Fig.1 b+e) which could be removed by two cyanoacrylate biopsies 
(Fig.1 c+f). In agreement with that, fluorescence microscopy showed decreasing nano screen-MAG 
fluorescence intensity from tape 1 to 7, while no fluorescence was present on tape 8 to 10 and on the 
surface of tape striped skin (Fig.2a). The fluorescence intensity (excitation wavelength 476 nm, emission 
wavelength 490 nm) quantified after extracting the tapes decreased steadily from tape 1 to 10, with less 
than 1.5% of the total applied amount being found in the last two tape strips (Fig. 2b). Three different 
regions of interest were defined (ROI): (ROI 1) an area supposedly being covered with NP, (ROI 2) the 
hair, and (ROI 3) the skin surface (Fig. 3a). Spectral analysis revealed the molecules typical of the 
respective areas, i.e. (ROI 1) iron indicating the magnetite core of nano screen-MAG, (ROI 2) carbon and 
sulfur indicating the hair disulfide bonds of hair keratin, and (ROI 3) carbon indicating the skin surface 
(Fig. 3b). In summary these analyses confirmed the efficacy of surface cleaning by ten tape strips and 
gave convincing evidence that the fluorescence recovered from cyanoacrylate biopsies is representative 
of the HF content.  
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Fig. 1:  Skin distribution of nano screen-MAG NPs (100 nm, magnetite core, chitosan coated, 
fluorescence labeled, λex 476 nm, λem 490 nm) investigated on pig ear skin. a-c: Scan images (scale 
bar = 5 mm); d, e: ESEM images, f: Confocal microscopy of a cyanoacrylate biopsy, a focal plane of a 
representative HF (scale bar = 100 µm); a+d: NPs are distributed homogeneously across the incubation 
site; b+e: After application of ten tape strips no NPs remain on the skin surface. NPs deposited in the HFs 
are clearly visible; c+f: A cyanoacrylate biopsy performed after tape stripping. The content of the HF is 
incorporated in the polymerized cyanoacrylate, NPs are clearly visible. 
a 
e f 
b c 
d 
Quantification of nanoparticle uptake into hair follicles 
24 
 
 
Fig. 2:  Pig ears were incubated with nano screen-MAG NP and differential stripping was 
performed as described. (a-c) Transmission images showing stratum corneum removed by tape 
stripping and (d-f) showing fluorescence from nano screen-MAG NP (λex = 458 nm, band pass filter 
520-555 nm LSM 510 Meta, Carl Zeiss GmbH, Jena Germany). Nano screen-MAG NP are visible on 
tape strip #1 (a, d) and #2 (b, e), but no longer on tape strip #10 (c, f).  
(g) Skin was incubated with FITC labeled PLGA NPs (light grey bars), Chit.-PLGA NPs (dark grey 
bars) and DPPC-Chit.-PLGA-NPs (white bars) and differential stripping was performed as described 
(In vitro: pig ear skin (plain bars), in vivo: human forearm (striped bars)). The samples were 
extracted and fluorescence intensity was quantified to calculate %recovery. Less than 1.5% of the 
total applied amount of any NP was found in tapes 9+10. 
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Fig. 3:   (a) ESEM image of pig ear skin incubated with nano screen-MAG NPs after performing 
ten tape strips. ROIs were defined on areas supposedly containing NPs (ROI 1), the hair (ROI 2) and on 
the skin surface (ROI 3) and spectral analysis was performed (b). Iron from the nano screen MAG NP core 
was detected only in ROI 1. 
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3.3.3 METHOD VALIDATION 
 
LLOQ were similar for pig ear and human skin which is important for IVIVC. The intra-ear variability for 
cyanoacrylate biopsy, application device, and skin rest was smaller than the inter-ear variability. Only for 
tape strips intra- and inter-ear variability were similar. Consequently, for each ear a new blank 
experiment needs to be performed, however it is sufficient to perform just one blank experiment per 
ear.  
The brightness of the NP fluorescence and the background fluorescence of the matrix determine the 
LLOQ and therefore represent the analytical constraints of the quantification method.  
Table 2 summarizes linear range of particle fluorescence in ACN  :  0.1 N NaOH 70:30 and LLOQ. Due to 
the different types of matrix LLOQ is different for tape strips, cyanoacrylate biopsies, skin rest (in vitro)/ 
cotton swab (in vivo), and application devices (glove finger, pipette tip). LLOQ was calculated for each 
type of matrix from mean fluorescence intensities obtained from blank experiments applying water 
instead of NP plus three times the standard deviation. For tape strips, cyanoacrylate biopsies, application 
device, and the skin rest 17 out of 138, 2 out of 46, 3 out of 14, and 2 out of 23 (in vitro) and 4 out of 66, 
3 out of 22, 1 out of 6, and 0 out of 11 (in vivo) were discarded as outliers, respectively. The highest LLOQ 
was measured in cyanoacrylate biopsies which are therefore the limiting factor of this quantification 
method (Table 2).  
For example, LLOQ should not be higher than 3.75-7.5 µg/ml to be able to quantify 1-2% of the applied 
amount in each matrix type (assuming that 15 µl of a 50 mg/ml NP dispersion are applied onto the skin). 
This was the case for all NP and matrices in vitro as well as in vivo. LLOQ were similar for pig ear and 
human skin which is important for IVIVC. 
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The intra-ear variability for cyanoacrylate biopsy, application device, and skin rest was smaller than the 
inter-ear variability. Only for tape strips intra- and inter-ear variability were similar (data not shown). 
Consequently, for each ear a new blank experiment needs to be performed, however it is sufficient to 
perform just one blank experiment per ear. 
 
Table 2  Linear range of particle fluorescence and LLOQ are reported as NPs concentration in 
ACN: 0.1 N NaOH, 70:30, [µg/ml]. LLOQ was calculated for each type of matrix from mean fluorescence 
intensities obtained from blank experiments applying water instead of NP plus three times the standard 
deviation (n=23 and 11 for pig ear skin and human skin, respectively).  
  PLGA Chit.-PLGA DPPC-Chit.-PLGA 
Linear range [µg/ml] 1-375 (r²>0.999) 0.07-26 (r²=0.999) 0.07-26  (r²=0.999) 
LLOQ [µg/ml] in vitro in vivo in vitro in vivo in vitro in vivo 
Tape strips 0.18  0.23 0.03 0.03 0.04 0.04 
Cyanoacrylate biopsies 3.83 4.12 0.54 0.58 0.75 0.81 
Skin rest/cotton swab 1.90 0.55 0.27 0.08 0.37 0.11 
Application device 0.17 0.33 0.02 0.05 0.03 0.06 
 
3.3.4 NP UPTAKE INTO HAIR FOLLICLES IN VITRO AND IN VIVO 
 
Tape stripping is a minimally invasive technique which is regularly applied in human volunteers in vivo, 
for example as a method for determining bioavailability of topically applied formulations [68]. We 
monitored by measuring transepidermal waterloss (TEWL) that also differential stripping by adhesive 
tape and subsequent application of two cyanoacrylate biopsies can be applied in human volunteers and 
is minimally invasive (Fig. 4). Baseline TEWL (Biox Aquaflux AF 200, Biox Systems Ltd., London, UK) of a 
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control area of untreated skin remained constant during the whole experiment. After 10 x tape stripping, 
TEWL increased only slightly above baseline indicating negligible barrier damage (from 
14.30 ± 1.21 g/m²/h to 18.69 ± 2.29 g/m²/h; mean ± SD of n = 20 respectively). After two cyanoacrylate 
biopsies TEWL increased distinctly to 64.70 ± 25.75 (Fig. 4a, mean ± SD of n = 20), and remained high 
during the following 24 h. Typically TEWL > 60 g/cm²/h indicates significant skin damage due to complete 
SC removal [69]. A slight inflammation of the treated area is expected and disappears within several 
days. TEWL was monitored in one volunteer until full recovery of baseline values which was observed 
after 4 days (Fig. 4b). 
 
 
Fig. 4:  a: In human volunteers TEWL was measured before the experiment, after 10 x tape stripping, 
after cyanoacrylate biopsies and again after a recovery time of 2 h and 24 h on one untreated area (baseline, filled 
triangles), one blank incubation sites (dd water, open circle), and on up to three NP application sites (filled circles). 
(mean ± SD of n = 10 for blank incubation sites and untreated skin, and n=25 for NPs); b: In one volunteer, 
additionally TEWL was monitored until full barrier recovery after 4 days, this volunteer received NP on 3 application 
sites (mean ± SD, filled circles), one blank incubation site (open circles). Base line TEWL was monitored on one 
untreated skin area (filled triangles). 
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Table 3 shows the fractions of NP which were recovered from the individual types of samples in vitro 
obtained from pig ears and in vivo from the forearms of human volunteers. The absolute amount of NP 
in each sample was determined by fluorescence quantification and related to the total amount of NP 
applied onto the skin to obtain recovery% (0.424 mg PLGA NP/cm² and 0.059 mg plain or PL coated Chit.-
PLGA NP, all representing finite doses). Total recovery% represents the sum of the NP found in all types 
of samples. OECD (Organisation for Economic Cooperation and Development) test guidelines for skin 
absorption testing in vitro and in vivo highly recommend mass balance for finite dose studies and define 
an adequate recovery of 100 ± 10% [70, 71], SCCNFP (Scientific Committee on Cosmetic Products and 
Non-food Products) accepts 100 ± 15% [72]. Total recovery% usually met the OECD criteria and was 
always within the SCCNFP limits (Tab. 3). 
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Table 3  NPs recovered from skin surface, HF, and application device and skin rest (in vitro)/ cotton swab 
(in vivo) and reported as % (wt/wt) of the total applied dose. Mean ± standard deviation (SD) of n = 8, 17, 6, 5 for 
PLGA-NPs in vitro, and in vivo and for Chit.-PLGA-NPs and phospholipid coated--Chit.-PLGA-NPs in vitro, and in vivo 
respectively. 
 PLGA NP Chit.-PLGA 
NP 
DPPC : Chol 
(85:15) 
coated Chit.-
PLGA NP 
DPPC : 
DOTAP 
(92:8) coated 
Chit.-PLGA 
NP 
DPPC (100) 
coated      
Chit.-PLGA 
NP 
 in vitro 
Skin surface 48.06 ±  8.61 89.79 ± 3.64 86.42 ± 3.36 89.76 ± 5.27 91.71 ± 3.85  
HF  3.61 ±  0.95 3.15 ± 1.23 2.16 ± 1.11 6.04 ± 2.13 6.95 ± 2.30 
Skin rest 0.56 ± 0.54 0.05 ± 0.11 0.11 ± 0.09 0.12 ± 0.09 0.25 ± 0.20 
Application 
device 
32.26 ± 11.57 5.96 ± 1.93 9.49 ± 4.62 5.28 ± 1.53 9.62 ± 2.85 
Total 
recovery 
84.48 ± 6.82 98.96 ± 5.27 98.10 ± 4.41 101.22 ± 6.09 108.53 ± 6.82 
 in vivo 
Skin surface 55.32 ± 8.22 81.02 ± 11.23  84.72 ± 3.99 84.03 ± 5.48 85.26 ± 2.88  
HF  4.82 ± 2.72 1.45 ± 0.57 1.75 ± 0.75 3.80 ± 1.58 5.63 ± 3.45 
cotton swab 0.40 ± 0.54 0.01 ± 0.03  0.01 ± 0.03 0.02 ± 0.02 0.06 ± 0.07 
Application 
device 
29.37 ± 8.10 7.15 ± 3.07 7.95 ± 3.82 5.86 ± 1.48 6.97 ± 2.26 
Total 
recovery 
89.91 ± 
10.14 
89.63 ± 9.05 94.43 ± 5.0 96.17 ± 2.52 98.10 ± 4.41 
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Full mass balance should replace the common praxis in differential stripping studies of reporting relative 
numbers: usually, the amount recovered from the HF is normalized to a reference value, e.g. by 
comparing NP versus solutions [73], the same NP formulation over time [47], or worse, the amount 
recovered from the HF is related to the amount recovered from the skin surface. This HF/surface ratio is 
in principle an interesting number to demonstrate the relative distribution of NP. However, Teichmann 
et al. reported a total recovery of only 54±8% for sodium fluorescein  solution with the remaining 46% 
not being accounted for [57]. Problems arise if recovery varies between repetitions, different 
formulations, or between the different samples obtained (i.e. the recovery is different from tape strips 
and cyanoacrylate biopsies) as it can seriously distort results. The major advantage of reporting absolute, 
non-normalized numbers is that the absolute amount of active pharmaceutical ingredient or NP taken up 
into HF can be determined. This number is relevant to determine the deposited dose.  
By quantitative differential stripping analysis we found that, although the major fraction of NP remained 
on the skin surface (48-55% when NP were applied with a gloved forefinger, 81-92% when NP were 
applied by pipetting), depending on NP material 1.45-6.95% of the applied NP penetrated into the HF 
(Tab. 3). The different fractions deposited on the skin surface are clearly linked to the different fractions 
of NP remaining on the application devices (ca. 30% when NP were applied with a gloved forefinger, ca. 
5-10% when NP were applied by pipetting, Tab. 3). Furthermore, both in vitro and in vivo follicular 
uptake was dependent on NP material. In vitro in pig ears DPPC coated, and DPPC : DOTAP (92 : 8) 
coated Chit.-PLGA were those NP which were taken up to the highest extent, while plain PLGA, Chit.-
PLGA and DPPC : Chol. (85 : 15) coated Chit.-PLGA NP were taken up less efficiently. Differences between 
both DPPC coated as well as DPPC : DOTAP (92 : 8) coated Chit.-PLGA NP and each of the other NP, i.e. 
plain PLGA, Chit.-PLGA and DPPC : Chol. (85 : 15) coated Chit.-PLGA NP were significant (Tab. 3, Fig. 35, 
one-way ANOVA with Holm Sidak all pairwise multiple comparison, p<0.05 indicating significance). To 
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confirm these findings, the experiments were repeated in human volunteers. The outer forearm was 
chosen as this is more densely covered with follicles than the inner forearm (which usually would be the 
recommended application site for testing delivery from topical formulations in vivo in humans [70]. The 
same phenomenon of two groups was found. In vivo the difference between plain PLGA, DPPC coated, 
and DPPC : DOTAP (92 : 8) coated Chit.-PLGA NP on the one hand and Chit.-PLGA and DPPC - Chol. 
(85 : 15) coated Chit.-PLGA NP was more obvious (Tab. 3 Fig. 5a). However, due to a higher variability of 
the in vivo data the differences were not statistically significant (one way ANOVA with Holm Sidak all 
pairwise multiple comparison, p<0.05 indicating significance). To test the hypothesis that the pig ear is a 
suitable model for the situation in man for quantifying follicular uptake of NP, we correlated in vitro with 
in vivo results by plotting mean ± SD of % recovery from all sample fractions (except skin rest and cotton 
swab as different methods were applied in vitro and in vivo) and found an excellent linear IVIVC 
(r²=0.987, Fig. 4b). Additionally we correlated the in vitro versus in vivo mean recovery% only from the 
HF and still obtained a distinct relationship which is however not as clear due to the high variability of 
the individual data points (r²=0.577, Fig. 5c).  
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Fig. 5:  a: Recovery from the hair follicle of topically applied fluorescence labeled PLGA-,Chit.-
PLGA-NP, and NP coated with DPPC:Cholesterol (85 : 15), DPPC:DOTAP (92 : 8) and DPPC (100) in vitro on 
the pig ear (black bars) and in vivo on the human forearm (grey bars); mean ± SD of n = 8/ 17 for PLGA-
NPs in vitro/ in vivo and n = 6/5 for Chit.-PLGA-NPs and PL coated Chit.-PLGA-NPs in vitro/ in vivo 
respectively. b: IVIVC including the amounts recovered from the skin surface, the HF, the application 
device and total recovery; mean ± SD and line of identity; r² = 0.987 c: IVIVC focusing only on the 
recovery from the HF, mean ± SD and line of identity  
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In conclusion, although the pig ear in vitro model slightly overestimated the differences between the NP, 
the trend that was observed in human volunteers was predicted correctly. Although pig skin is generally 
considered an appropriate model for topical absorption across human skin and especially with regards to 
the absorption of particle based formulations, this result could not be expected due to the anatomical 
differences between human and porcine hair follicles. The dorsal site of the porcine ear is commonly 
used for skin penetration experiments as it represents the highest similarity to human skin regarding the 
permeability [74]. On pig ear the number of hair follicles averages 20 hairs per cm² [74], in human 18 
hairs per cm² on the forearm [45]. Although hairs of porcine ear are approximately five times thicker 
than human vellus hair, it is similar to human terminal hair [74]. Thus the porcine ear provides a skin 
model suitable to mimic the human forearm in size and number of hair follicles. Valid skin models for the 
in vitro testing of NP for transfollicular delivery are needed to characterize and to optimize NP as 
potential drug carries for topical application.  
A striking result of the present study was the differences in follicular uptake that we recorded for the 
different NP. Selectivity for a certain size, charge or chemical features are basic features ensuring 
meaningful interaction of tissues, cells, or receptors with self and foreign entities. For NP no systematic 
investigation has been undertaken yet to elucidate this issue as introduced above. By using NP which had 
very similar hydrodynamic sizes we aimed to investigate the influence of particle material. Keep in mind 
that hydrodynamic size and zeta potential (i.e. NP mobility in an electric field) are parameters which are 
measured in highly dilute aqueous dispersion of the particles. Their behavior after application onto the 
skin is currently a black box which is not trivial to elucidate. Phenomena occurring after topical 
application of these NP formulation likely include drying, possibly particles aggregate or may interact 
with the skin surface hydrolipid film as well as the sebum from the HF. Focusing for once on the results 
obtained in human volunteers in vivo as the gold standard, it is remarkable that plain PLGA NP as well as 
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DPPC coated and DPPC : DOTAP (92 : 8) coated Chit.-PLGA NP penetrated into the HF to a higher extent 
than Chit.-PLGA NP and DPPC : Chol. (85 : 15) coated Chit.-PLGA NP (Table 3, Figure 5a). Discussing the 
plain PLGA and Chit.-PLGA NP separately from the PL coated NP, two separate effects appear. First of all 
plain PLGA NP were the only NP with a nominally negative zeta potential. It has been shown before by 
Lee and coworkers that negatively charged NP interact more effectively with the skin surface than 
positively charged NP, which may explain the higher follicular uptake compared to e.g. positively charged 
Chit.-PLGA NP [75]. Secondly, we hypothesize that lipid coating or in general lipophilic material 
properties of NP favor their uptake into the lipid rich environment of the sebum filled HF, as we have 
seen for the DPPC and DPPC : DOTAP coated NP (Table 3, Figure 5a). This leaves to explain the low 
follicular uptake of the DPPC : Chol. (85 : 15) coated Chit.-PLGA NP. Cholesterol is known to stiffen lipid 
bilayers which form the walls of liposomes [76]. Therefore during lipid coating of Chit.-PLGA NP the 
DPPC : Chol liposomes may spread less effectively on the NP surface, so that the coating is less complete 
than in the other PL coated NP. Hence, DPPC : Chol. (85 : 15) coated Chit.-PLGA NP are more similar to 
the Chit.-PLGA NP than the other PL coated NP, which is reflected in their similar low uptake into HF. This 
hypothesis is further supported by the zeta potential data (Table 1). DPPC coated Chit.-PLGA NP had a 
lower zeta potential than Chit.-PLGA and DPPC : Chol. (85 : 15)-coated Chit.-PLGA NP reflecting a better 
coating of the Chit.-PLGA NP and therefore a more effective shielding of the surface charge of chitosan. 
This effect is masked in the DPPC : DOTAP (92 : 8) coated NP because DOTAP is a positively charged 
phospholipid, which compensates for the shielding of the charge of chitosan.  
We studied uptake into hair follicles of different fluorescently labeled NP and meaningful results were 
obtained which allow concluding on the best suitable NP system for follicular delivery. As fluorescence 
labeling was used for quantification, the brightness of the NP fluorescence and the background 
fluorescence of the matrix determine the analytical constraints of the quantification method. For 
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labeling with fluorescein it was helpful to use a mixture of ACN : NaOH to enhance the fluorescence 
intensity. The presented method can easily be modified to be applicable to different carrier systems and 
issues. Different fluorescent labels may require modifications in the solvent composition and 
measurement settings. A method transfer to other types of nanoparticles and fluorescent labels was 
successfully performed in our institute.  
The method may further be expanded to drug loaded carrier systems. With the implementation of for 
example HPLC analytics it would be possible to distinguish between the fate of the NP and the 
penetration and location of the drug load. As in our study large polymeric NP were used tape stripping 
was only performed to clean the skin surface from remaining NP formulation but not to sample the SC. If 
drug loaded NP shall be investigated the number of tape strips can be enhanced to perform depth 
profiling of the penetrated drug into the SC in parallel. In this case the use of a method to determine the 
amount of SC removed by each tape strip, e.g. infrared densitometry, or protein quantification, is highly 
recommended in order to accurately determine the position inside the SC. 
 
3.4 CONCLUSION 
 
Differential stripping was a suitable method to quantify the distribution of five different fluorescently 
labeled pharmaceutically relevant NP with sufficient sensitivity provided that the fluorescence labeling of 
the particles is bright enough. The most critical sample when using FITC labeled NP is the cyanoacrylate 
biopsy of the HF as this sample has the highest matrix background (which will of course depend on the 
particulars of the analytical method such as the extraction solvent and the quantification method). 
Follicular uptake of the tested NP was material dependent. Plain PLGA NP with negative zeta potential 
and DPPC coated and DPPC : DOTAP (92 : 8) coated Chit.-PLGA NP penetrated into the HF to a higher 
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extent than Chit.-PLGA NP and DPPC : Chol. (85 : 15) coated Chit.-PLGA NP which may indicate that 
negative surface charge as well as lipophilic surface properties may facilitate follicular uptake. 
The pig ear in vitro model is a suitable model for quantifying follicular uptake. It is well suited to optimize 
NP based drug delivery systems for follicular drug targeting. 
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4. INFLUENCE OF APPLICATION TECHNIQUE ON THE UPTAKE OF 
NANOPARTICLES INTO THE HAIR FOLLICLE 
 
 
Influence of application technique 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contributions to this chapter: 
Planned, performed and interpreted all major experiments. 
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4.1. INTRODUCTION 
 
It was shown in the previous chapters that only very small amounts of topically applied NP (less than 
10% of the applied amount) penetrate into the HF. The major amount of particles remains on the SC 
surface which acts as a barrier particles and large cargo-molecules (e.g. vaccine antigens) cannot 
overcome (Ref). Transfollicular vaccination aims at eliciting a protective immune response via the 
application of nanoparticle encapsulated antigen (with or without adjuvant) via the HF without impairing 
the SC barrier function. This aim should be achieved by optimizing the targeting of the deep hair follicle 
where facilitated penetration conditions and a high density of antigen presenting cells are present. To 
succeed in transfollicular vaccination the penetration efficiency needs to be optimized. Lademann et al. 
showed in vitro in the pig ear model that massage enhances the depth of penetration of particles into 
the follicle [19]. They hypothesized that massage mimics the natural movement of hair in the in vitro 
model and the hairs act like a gear pump which transports the nanoparticles deeper into the hair follicle.  
Using the quantification method described in chapter three it was investigated if the described effect of 
massage enhances not only the penetration depth but also the amount of NPs taken up into the hair 
follicle. Fluorescently labeled PLGA NP were applied on pig ears i) without massage, ii) with manual 
massage using the gloved forefinger and iii) with the help of a mechanic massaging device which also 
vibrates to investigate whether vibration may be of added value and to achieve a more homogeneous 
distribution of force.  
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4.2. MATERIAL AND METHODS 
 
4.2.1. PIG EAR SKIN 
 
Pig ears were obtained from a local abattoir. The ears were removed from the carcass before scalding. 
After washing and blotting dry with tissue the ears are stored up to two days at 2 – 8°C.  
4.2.2. NANOPARTICLES 
 
FITC labeled PLGA-NP as described in chapter 3 were used (average hydrodynamic diameter of 162.8 ± 
0.06 nm, size distribution PDI 0.06 ± 0.01, negative zeta potential of - 33.6 ± 2.5 mV, see chapter 3.2.3 
and 3.3.1).. Briefly, the particles were prepared by a double emulsion method described in [48]. PLGA NP 
were stored as freeze-dried powder and re-suspended in dd water to obtain the desired concentration 
prior to use 
4.2.3. APPLICATION PROTOCOL AND SAMPLING 
 
The pig ears were blotted dry with tissue and allowed to dry completely. Hairs were shortened with 
scissors and incubation sites of 1.767 cm2 were marked with water resistant marker. 15µl of PLGA NP 
suspension were applied on the application site and i) distributed homogeneously over the incubation 
site, ii) massaged manually with a gloved forefinger for three minutes or iii) massaged with a vibrating 
massage device (Mini Massage Stick, Royal Wellness) for three minutes. On each ear one area was 
treated with each different massage techniques with blank formulation (dd water) to determine the 
analytical background. 17 areas on 7 ears were treated without massage, 17 areas on7 ears were treated 
with manual massage and 6 areas on 3 ears were treated with vibration. The pig ears were kept in an 
incubator at 32 °C without coverage for 1 hour. After incubation the NPs were sampled and analyzed as 
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described in chapter 3. Briefly, (a) 10 Tape strips were taken to collect NP remaining on the skin surface. 
(b) Two cyanoacrylate biopsies were performed to collect the cast of the HF which contains the NP 
penetrated into the hair follicles. (c) A punch biopsy of 4.91 cm² including the incubation site was taken 
to sample NP remaining in the skin rest. (d) Also the application devices (pipette tip for application 
without massage, glove fingers for application with manual massage and vibration). 
4.2.4. SAMPLE EXTRACTION AND ANALYSIS 
 
All samples were extracted in ACN : 0.1 N NaOH (70:30) for three hours under light exclusion and then 
centrifuged (5 min, 20 °C, 24651 g). Fluorescence intensities of all samples were measured (excitation 
λex = 490 nm, emission λem = 525 nm) in a plate-reader (TECAN infinite M200, Tecan GmbH, Crailsheim, 
Germany). For calibration, a stock suspension with known NP concentration (wt/V) was prepared in 
ACN : 0.1N NaOH (70:30), extracted for three hours and diluted with ACN : 0.1N NaOH to obtain 
standards.  
4.2.5. STATISTICS 
Statistical testing was performed by one-way ANOVA with Holm-Sidak all pairwise multiple comparison 
procedure. A p value of ≤ 0.05 was considered significant. 
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4.3. RESULTS 
 
Fluorescently labeled PLGA nanoparticles were applied on defined incubation sites on pig ear skin 
without massage, with manual massage and with a vibrating mechanic massaging device. The fraction of 
the applied nanoparticles that penetrated into the hair follicles was assessed. Full recovery, which is 
defined according to the guideline of the within the limits of 100 ± 15%, was found in all experiments. 
Without massage 26.87 ± 22.87 µg of the applied nanoparticles were found inside the hair follicles which 
is equivalent to 2.85 ± 2.19 % of the totally applied amount of particles. All results are summarized in 
Tab. 1. Figure 1 A summarizes the recovery from skin surface, hair follicle, skin rest, application device 
and the total recovery. Figure 1 B shows the influence of the different application techniques to the 
uptake into the hair follicle. With manual massage the uptake into the hair follicle increased to 
27.00 ± 9.50 µg (3.59 ± 1.26 %). Application with the vibrating massaging device lead to an uptake of 
particles into the hair follicle of 19.62 ± 8.49 µg (2.54 ± 1.10%). The differences between the application 
techniques were not statistically significant.  
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Table 1   NPs recovered from skin surface, HF, and application device and skin rest reported as % 
(wt/wt) of the total applied dose. Mean ± standard deviation (SD) of n = 17 for performance without 
massage and manual massage and n = 6 for vibration.   
Recovery [%] 
 
Without massage Manual massage  Vibration 
Tape strips 
 
90.04 ± 6.89 53.98  ± 10.86 42.36 ± 7.25 
Cyanoacrylate Biopsies 
 
2.85  ± 2.19 3.59  ± 1.26 2.54  ± 1.10 
Application device 
 
4.63  ± 1.54 31.60  ± 8.44 40.47  ± 10.48 
Total recovery 
 
96.56  ± 6.73 89.11  ± 7.92 88.54  ± 8.28 
 
 
 
 
 
 
 
 
Fig. 1:   Recovery of topically applied fluorescently labeled PLGA-NPs from pig ear skin. Particles 
were applied without massage (black bars), with manual massage (light grey bars) and with vibration 
(dark grey bars). A: amount of nanoparticles recovered from skin surface, HF, appl. Device and skin rest. 
B: amount of nanoparticles recovered from the hair follicle. Not statistically relevant difference between 
the application techniques.  
A B 
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4.4. DISCUSSION 
 
Lademann et. al found that massage enhances the penetration depth of particles inside the HF by 
analyzing the location of NPs in the HF in histological skin sections without focusing the quantitative 
aspect[19]. The quantitative impact of the application technique of massage is highly relevant regarding 
the potential use for tansfollicular application of NPs for medical purposes like vaccination. Massage is 
described to cause a movement of hairs which makes them act like a gear pump, transporting the NPs 
deeper into the hair bulb. To differentiate the effect of moving hairs and of vibration both techniques of 
massage were applied manual massage which only moves the hairs and massage using a vibrating 
massage device which applies massage additionally to the movement of hairs.  
Neither manual nor vibrating massage enhances the uptake into the HF. It can be assumed that the 
major amount of NP is deposited in the infundibulum of the follicles and only very small amounts 
penetrate deeper into the follicle [77]. It seems as massage enhances the penetration depth of the 
fraction of deeply penetrating particles but not its amount. The LLOQ for FITC-labeled PLGA NPs was 
determined to be 375 µg/ml, which is equivalent to one percent of the applied amount of particles per 
incubation site. We assume the amount of particles that penetrate deeply into the follicle by the 
application of massage comes below the limits of the method. As a consequence it can be hypothesized 
that even if the application of massage has a quantitative effect, it enhances the total uptake into the HF 
not more than one percent of the applied dose.  
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4.5. CONCLUSION 
 
To summarize, massage might be an interesting method to support the targeting to deeper regions of 
the follicle but it is inappropriate to enhance the total amount that can be successfully delivered into the 
HF. The overall amount of nanoparticles that can be delivered into the hair follicles is thus limited. This 
limits the application of transfollicular delivery to highly active drugs. It might still be an option for 
transfollicular vaccine delivery or transfollicular hypodesensitization for curative therapy of allergies
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5. NON-INVASIVE DELIVERY OF NANOPARTICLES TO HAIR FOLLICLES 
– A PERSPECTIVE FOR TRANSCUTANEOUS IMMUNIZATION 
 
 
Non-invasive delivery of nanoparticles to hair follicles 
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5.1. INTRODUCTION 
 
TCI refers to the needle-free application of vaccines across the skin [78]. Major benefits include the 
possibility of self-administration, improved patient compliance, no requirement of “sharps” waste 
removal, and reduced storage and transport issues. The skin is a superior organ for eliciting an immune 
response compared to the muscle due to the abundance of professional APCs such as dendritic cells 
(DCs) and Langerhans cells (LCs) in different layers of the skin [79, 80]. In addition, TCI can generate both 
a humoral as well as a cellular response at the site of administration and also at distant mucosal sites 
[22]. Hence, TCI may allow reducing the antigen dose, as well as eliciting an improved immune response 
in persons with a disease- or age-compromised immune system [81].  
The major challenge for TCI is to enhance the transport of antigens across the stratum SC barrier. To this 
end often barrier disrupting measures are applied, such as chemical permeation enhancers, abrasion, 
electroporation, micro-needles, PowderJect, gene gun, etc. [82]. In contrast, transfollicular vaccination 
aims to deliver antigens to the abundant perifollicular APCs [14, 83]. Any additional barrier disrupting 
measures should be expendable as the SC only extents into the upper third of the follicle. Solid NPs are 
the ideal vehicles for transfollicular delivery as they accumulate in HFs and skin folds and penetrate 
deeper into hair follicles than molecules in solution [56]. Transfollicular delivery has been widely 
investigated for DNA vaccines, and lately also for non-nucleotide based antigens such as a seasonal flu 
vaccine as well as NP based formulations  
Nonetheless, transfollicular vaccination is usually performed after pretreating the skin area by plucking 
the hairs, waxing, or cyanoacrylate (superglue) stripping. This pretreatment induces the hair cycle into 
anagen (proliferation) state and markedly increases the transfection efficiency of follicular keratinocytes 
[15, 84]. The pretreatment is therefore helpful for DNA vaccines, however, it may be expendable for 
protein or peptide based antigens. At the same time the SC is (at least partially) removed so that it is not 
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clear to which extent the antigen penetrates via the hair follicles or across the permeabilized SC. This is 
especially critical as the reduced barrier increases the risk of pathogen entry which is of particular 
importance for transfolliclular vaccination in (i) countries with critical hygienic conditions, and (ii) 
immuno-compromised individuals, such as elderly people with poor wound healing and young children.  
This study investigates the potential of transfollicular delivery of OVA using polymeric NPs without 
compromising the SC barrier by any pretreatment for the purpose of non-invasive TCI. NPs were 
prepared by a double emulsion method from PLGA or Chit.-PLGA and polyvinyl alcohol (PVA) as 
stabilizer. These are biocompatible and biodegradable polymers which are widely used for biomedical 
applications. The NPs were characterized physico-chemically in terms of size, surface charge, OVA 
encapsulation/loading and morphology. The integrity and biological activity of the encapsulated OVA 
was monitored by SDS page, in vitro proliferation of OVA-specific lymphocytes, and ELISA. The follicular 
delivery efficiency was measured in intact pig skin based on the differential stripping technique and 
compared to OVA solution [56, 85]. An adoptive transfer experiment was performed to verify the 
usefulness of the non-invasive transfollicular immunization route in vivo.  
To our knowledge this is the first study to evaluate the potential of transfollicular vaccination using NPs 
without applying SC barrier reducing measures. 
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5.2. MATERIALS AND METHODS 
 
5.2.1. MATERIAL 
 
EndoGrade® Ovalbumin (OVA) was obtained from Hyglos GmbH (Bernried, Germany); poly(d,l-lactide-co-
glycolide) (PLGA) (Resomer RG 50:50 H; inherent viscosity 0.31 dL/g) was kindly provided by Boehringer 
Ingelheim (Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany); polyvinyl alcohol (PVA) Mowiol® 
4-88 was obtained from Kuraray Specialties Europe GmbH (Frankfurt, Germany); ultrapure chitosan 
chloride salt (Protasan® UP CL113) was purchased from FMC BioPolymer AS (Oslo, Norway); trehalose 
was obtained from Sigma-Aldrich (St. Louis, MO, USA); fluorescein isothiocyanate conjugated ovalbumin 
(FITC-OVA) was obtained from Invitrogen (Molecular Probes Inc., Germany). Superglue was kindly 
provided by Uhu GmbH & Co.KG, (Bühl, Germany). Tesa film was obtained from TESA SE, Hamburg, 
Germany. The OVA specific ELISA kit was purchased from USCN life science Inc. (Hölzel Diganostik, 
Germany). All other solvents and chemicals used were of the highest grade commercially available. 
Deionized water (Milli Q Plus system, Millipore, Bedford, MA, USA) was used throughout the 
investigation. 
5.2.2. PIG EAR SKIN 
 
Ears from freshly slaughtered pigs were removed before scalding. The ears were washed with water, 
blotted dry and the hairs were shortened with scissors. The ears were stored at 4-8 °C for a maximum 
period of 3 days. 
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5.2.3. MICE 
 
Female BALB/c (H-2d) or C57BL/6 (H-2b) mice at the age 6-8 weeks were purchased from Harlan 
(Germany). OVA-TCR transgenic mice OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J), OT-II (C57BL/6-
Tg(TcraTcrb)425Cbn), and OT-IIxThy1.1 (C57BL/6-Tg(TcraTcrb)425Cbn Thy1a) were bred at the animal 
facilities of Helmholtz Centre for Infection Research under specific pathogen-free conditions. The animal 
experiment permission was given by the local government of Lower Saxony (Germany) with the No. 
33.11.42502‑04‑017/08. 
5.2.4. NANOPARTICLES PREPARATION AND CHARACTERIZATION  
 
5.2.4.1. Nanoparticle preparation 
 
PLGA NPs were prepared by a modified double emulsion method [86]. Briefly, 50 mg of PLGA were 
dissolved in 2 ml of ethyl acetate at room temperature. Then 400 μl of (1.875% wt/V) OVA solution in 
water was added to form a primary water-in-oil (w/o) emulsion. After sonicating at 6 W for 15 s, 4 ml of 
2% (wt/V) PVA solution was added to the primary emulsion and again sonicated at 12 W for 15 s. Water 
was added drop-wise to the resulting w/o/w emulsion under constant stirring to allow diffusion and 
evaporation of the organic solvent. The particles were collected by centrifugation at 15,000 g for 10 min, 
washed once with distilled water to remove excess surfactant and free drug and freeze dried using 
trehalose (0.2% wt/V) as cryoprotectant. 
Chit.-PLGA NPs were prepared in a similar manner as described above with the difference that Protasan® 
UP CL113 (0.2% wt/V) was added to the PVA solution.  
FITC labeled OVA loaded NPs and FITC labeled blank NPs were prepared by replacing OVA or the PLGA 
polymer with their fluorescent counterparts, respectively. 
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5.2.4.2. Nanoparticle characterization 
 
Size and ζ-potential of the NPs were analyzed by photon correlation spectroscopy (PCS) using a Nano-ZS 
(Malvern Instruments, Malvern, UK). The morphology of the NPs was characterized using scanning 
electron microscopy (SEM) (JSM 7001F Field Emission SEM (Jeol, Japan)) and atomic force microscopy 
(AFM) (Multimode V (Veeco, USA)). For SEM, prior to scanning, NPs were sputtered with gold (layer 
thickness approximately 10 nm). The accelerating voltage was 10 kV with a focal distance of 10 mm. For 
AFM imaging, NPs were scanned using tapping mode and scan rates of 0.6 Hz. A standard non-contact 
mode cantilever was used for imaging (OMCL-AC160TS, Olympus, Essex, Great Britain). 
The entrapment efficiency (% EE = wt OVA encapsulated/wt OVA added initially) and loading efficiency 
(% L = wt OVA encapsulated/wt polymer) of OVA in PLGA and Chit-PLGA NPs were determined using a 
QuantiPro bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA) according to the manufacturer’s 
instructions for 96 micro-well plates. Briefly, 5 mg of the lyophilized particles were hydrolyzed in 0.1 N 
NaOH for 6 h and then neutralized with 0.1 N HCl [86]. Blank NPs were used as a control.  
5.2.4.3. Integrity and Activity of OVA 
 
The integrity of OVA was determined by SDS PAGE analysis. Briefly, OVA was extracted from freeze-fried 
NPs under alkaline conditions (0.1 N NaOH). The total amount of protein was quantified using a 
QuantiPro BCA assay. A dose of 1 µg of OVA was loaded onto a 12% (wt/V) polyacrylamide gel under 
reducing conditions [87]. Detection of protein was performed by staining with colloidal Coomassie blue 
(Fermentas, St. Leonrot, Germany). 
To determine the activity of OVA encapsulated in NPs 1 ml of each NP dispersion (1 mg/ml) was 
incubated for 24 h in phosphate buffer (pH 5.5) at 32 °C under continuous stirring at 100 rpm. The 
dispersion was centrifuged for 20 min at 24,000 g and the total amount of protein in the supernatant 
was quantified using a QuantiPro BCA assay. Subsequently, the active OVA fraction was quantified using 
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an ELISA assay which was performed according to the instructions provided by the manufacturer. The 
ELISA was calibrated using standards provided by the manufacturer in the range of 0.156 – 10 ng/ml 
(LLOD = 0.053 ng/ml). Supernatant obtained from blank NPs were used as negative control. 
5.2.4.4. DC activation and stimulation: Preparation and flow 
cytometric analysis of murine dendritic cells 
 
Bone marrow-derived primary dendritic cells (conventional DCs) from C57BL/6 mice were generated by 
flushing femur and tibia of mice with media. Erythrocytes were lysed by adding ACK buffer (0.15 M 
NH4Cl, 1.0 M KHCO3, 0.1 mM EDTA, pH 7.2). Cells were washed and incubated on cell culture dishes for 
up to 2 h. Then non-adherent DC precursors in the supernatant were transferred to 12-well plates (2 x 
106/well) and differentiated for 5 days in media supplemented with 50 ng/ml GM-CSF. On day 5, DCs 
were co-incubated with PLGA OVA [10 µg/ml], Chit.-PLGA OVA and different controls, such as PLGA 
alone for 24 h at 37°C. Control cells were treated with OVA LPS free [10 µg/ml] and OVA co-administered 
with LPS derived from Salmonella enterica Serovar Typhimurium (Invivogene) at a final concentration of 
1 µg/ml. For flow cytometry, cells were pre-blocked using anti-mouse CD16/32 antibody for 15 min. 
Then, DCs were stained with several differentiation and maturation markers conjugated with different 
fluorochromes, such as CD40 (HM40-3), CD54 (YN1/1.7.4), CD80 (16-10A1), CD86 (GL1), MHC-II 
M5/114.15.2), and MHC-I (34-1-2S) antibodies 
(http://www.ebioscience.com/ebioscience/specs/antibody_17/17-5321.html, eBioscience, USA). The 
FACS analysis of 20,000 events was performed using a LSR-II and the FACSDiva software (BD Bioscience, 
USA), gating on CD11c positive cells. Results are expressed as mean of three independent experiments, 
standard error of the mean (SEM) is indicated by vertical lines. 
 
 
Non-invasive delivery of nanoparticles to hair follicles 
    53 
 
5.2.4.5. Measurement of cellular proliferation of antigen specific 
murine CD4+ and CD8+ T cells  
 
Differentiated murine DCs were incubated with 10 µg/ml of LPS-free OVA (EndoGrade® OVAlbumin, 
#321001, Hyglos, Germany), PLGA or PLGA-OVA and Chit.-PLGA or Chit.-PLGA-OVA. After 24h CD8+ T cells 
derived from spleens of OT-I mice, which have a transgenic T cell receptor specific for the OVA immune-
dominant peptide (aa 257-264, SIINFEKL) presented in the context of the MHC class I H-2Kb, or CD4+ T 
cells derived from spleen of OT-II mice expressing the TCR specific for OVA (aa 323–339, 
ISQAVHAAHAEINEAGR) presented in the MHC class II molecule I-Ab were isolated. Afterwards, the spleen 
cells were stained with 10 µM carboxy fluorescein succinimidyl ester (CFSE; Molecular Probes, USA) in 
PBS for 5 min and co-cultured with antigen stimulated murine DCs for 4 days. The loss of CFSE+ labelling 
of CD8+ and CD4+ T cells in response to stimulation with PLGA-OVA or Chit.-PLGA-OVA were determined 
by flow cytometry on a BD LSR-II and analysed using the FACSDiva software. Results are expressed as 
histograms and correspond to one representative experiment out of two independent tests.  
5.2.5. ADOPTIVE TRANSFER MODEL OF TCR TRANSGENIC CD4+ T CELLS TO 
CHARACTERIZE OVA SPECIFIC PROLIFERATION 
 
Immunization was carried on the flank part of the mice. In brief, 2 d before immunization mice were 
anesthetized and flanks were shaved using a razor. Shaved areas were carefully inspected for cuts or skin 
irritation in which case these mice were excluded from the experiment. One day prior to immunization 
OT-II x Thy1.1 mice derived naïve non-activated OVA-specific CD4+ T-cells (CD4+ CD62Lhi CD44lo CD25-) 
were isolated and subsequently sorted (purity ≥98%) using an ARIA II sorter (BD Biosciences, San Jose, 
USA). Then, CD4+ T-cells were labeled with CFSE (10 nM) and transferred to the shaved OVA naïve 
C57BL/6 mice by tail vein injection (1.5 x 106 per mouse). On the day of immunization, mice (n = 4) were 
immunized: (1) negative control, received Chit-PLGA + 2 µg c-di-AMP as adjuvant dispersed in 
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physiological buffer via i.m. injection; (2) positive control, received 200 µg / 50 µl LPS-free OVA dissolved 
in physiological buffer via i.m. injection; (3) received 200 µg / 60 µl LPS-free OVA in Chit-PLGA NPs + 2 µg 
c-di-AMP as adjuvant via transfollicular application.  
Four days post immunization the animals were sacrificed, immune cells were isolated from both spleens 
and draining lymph nodes (illiac and axillary LNs pooled) and stained (live/dead, CD3+, CD4+ and Thy1.1) 
separately for each animal. OVA specific proliferation (CFSE dilution) of viable CD3+, CD4+, Thy1.1 cells 
was analyzed using a LSRII flow. 
5.2.6. EVALUATION OF FOLLICULAR UPTAKE ON EXCISED PIG EARS 
 
Incubation sites of 1.767 cm² were marked on the outer auricle of the pig ears with a permanent marker. 
A dose of 15 µl of either an aqueous solution of FITC-OVA, an aqueous dispersion of FITC-OVA in PLGA 
NPs, or FITC-OVA in Chit.-PLGA NPs (8.5 µg OVA/cm², 0.16 and 0.13 mg NPs/cm² for PLGA NPs and Chit.-
PLGA NPs, respectively) were applied and massaged manually with a gloved forefinger for 3 min. The 
ears were incubated for 1 h at 32°C under non-occlusive conditions. 
5.2.6.1. Microscopical evaluation 
 
Cross-sections of 12 µm thickness were performed on a cryomicrotome (Cryostat Type MEV, Slee, Mainz, 
Germany). The biopsy was placed in a vertical direction relative to the blade to prevent the spreading of 
NPs from the skin surface to deeper skin layers. The sections were collected on objective slides, 
embedded in FluorSave™ embedding medium (Calbiochem®, USA) and sealed with a cover slip.  
For the top view image, a skin biopsy was mounted on an objective slide with distance holders and 
sealed with a cover slip, which immediately touched the skin as well as the distance holders to prevent 
any skin movement during the imaging process.  
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Cyanoacrylate biopsies were obtained as described below and fixed on an objective slide.  
All samples were imaged under the confocal microscope (Zeiss LSM 510 META system, Carl Zeiss, Jena, 
Germany). An Argon laser at 458 nm was used to excite the fluorescence signal. As objective a water 
immersion lens 25X was used. The high auto fluorescence of the skin was excluded by choosing 
appropriate filters and gain settings. In addition, for the cross-sections and cyanoacrylate biopsies 
transmission light images were superimposed with the fluorescence images. For top-view and 
cyanoacrylate biopsy images optical stacks (z-stacks) were performed. Image processing was performed 
using Volocity® 3D Imaging Analysis Software (Perkin Elmer Inc USA). 
5.2.6.2. Quantification of follicular uptake: Influence of encapsulating 
OVA into particles  
 
After the incubation the skin surface was cleaned from remaining formulation by removing 10 tape strips 
(Tesa kristallklar, Tesa SE, Germany). A roller was used to enhance the contact between tape strip and 
skin surface [66]. Subsequently, 2 cyanoacrylate biopsies were performed to collect the amount of OVA 
penetrated into the hair follicles. The cyanoacrylate biopsies were extracted in ACN : 0.1 N NaOH (70:30) 
for 3 h on a horizontal shaker and the fluorescence intensity of all samples was measured using a Tecan 
platereader (Excitation 490 nm, Emission 525 nm). The amount of FITC-OVA extracted from the 
cyanoacrylate biopsies was calculated with the help of standards prepared from FITC-OVA / FITC-OVA in 
PLGA NPs / FITC-OVA in Chit-PLGA NPs dissolved in ACN : 0.1 N NaOH (70:30) in the range of 0.1-10 
µg/ml. The results for the NPs were expressed relatively to FITC-OVA solution.  
Blank samples were taken from an incubation site of the same pig ear; double distilled water was applied 
instead of NPs. The blank values were subtracted from the fluorescence intensity of the samples. 
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5.2.6.3. Quantification of follicular uptake: Influence of particle 
concentration 
 
Follicular uptake was quantified using particle concentrations of 0.22/0.42/0.85 mg NPs/cm². Briefly, 
15 µl of each NP dispersion at a concentration of 25/50/100 mg NPs/ml were applied to an area of 1.767 
cm² and processed exactly as described above. The NPs used in these experiments were prepared using 
FITC-PLGA to enable detection and did not contain any OVA. FITC-labeling of PLGA was performed as 
described in [64]. Standards were prepared from blank FITC-PLGA or Chit.-FITC-PLGA NPS in the range of 
5-380 µg/ml dispersed in ACN : 0.1 N NaOH (70:30). Blank samples were taken from an incubation site of 
the same pig ear; double distilled water was applied instead of NPs. The blank values were subtracted 
from the fluorescence intensity of the samples. 
5.2.7. STATISTICAL ANALYSIS 
 
Statistical analysis was performed by a one-way ANOVA. A p value of ≤ 0.05 was considered significant. 
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5.3. RESULTS 
 
5.3.1. CHARACTERIZATION OF NANOPARTICLES 
 
The SEM and AFM images in Fig.1 show smooth, spherical particles. The characteristics of the NPs are 
summarized in Table 1. The mean size of OVA loaded PLGA and Chit.-PLGA NPs was ca. 170 nm and 
180 nm, respectively, with a monodisperse size distribution (PDI < 0.2). PLGA NPs have a negative surface 
charge whereas Chit.-PLGA NPs have a positive surface charge. Antigen incorporation into PLGA and 
Chit.-PLGA NPs slightly increased the particle size and reduced the overall surface charge compared to 
blank NPs. For both particle types similar %EE of 27.61 ± 2.52% and 36.54 ± 2.44% and %L of 5.43 ± 
0.47% and 6.65 ± 0.44% were obtained (for PLGA and Chit.-PLGA NPs respectively). 
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Table 1 Physico-chemical characterization of the optimized PLGA and Chit.-PLGA NPs 
Values represent mean ± standard error of the mean (SEM) of n = 6 independently prepared batches, 
except for %A where n = 3. Z.P. zeta potential, %EE encapsulation efficiency (wt OVA encapsulated/wt 
OVA added initially), %L loading (wt OVA encapsulated/wt polymer), %A activity (wt OVA active/OVA 
encapsulated) 
Nanoparticle Size (nm) PDI Z.P. (mV) % EE % L %A 
Blank PLGA 162.8 ± 
1.66 
0.056 ± 
0.005 
-31.5 ± 
1.03 
- -  
OVA loaded PLGA 168.5 ± 
1.45 
0.063 ± 
0.008 
-24.8 ± 
0.89 
27.61 ± 
1.03 
5.43 ± 
0.19 
73.59 ± 
2.91 
Blank Chit-PLGA 171.5 ± 
1.36 
0.123 ± 
0.012 
24.1 ± 
0.78 
- -  
OVA loaded Chit-
PLGA 
183.6 ± 
2.71 
0.171 ± 
0.012 
20.2 ± 
1.05 
36.54 ± 
1.08 
6.65 ± 
0.18 
63.57 ± 
2.68 
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Fig. 1:  Top: (a) & (b) SEM and AFM images of OVA loaded PLGA NPs; bottom: (c) & (d) SEM and 
AFM images of OVA loaded Chit.-PLGA NPs 
 
5.3.2. INTEGRITY AND ACTIVITY OF OVA 
 
To investigate the formation of fragments or aggregates of OVA during NP preparation, an SDS PAGE was 
performed. Weak differences in the migration pattern of OVA extracted from NPs compared to control 
(OVA in aqueous solution) were observed as shown in Fig. 2(a). While no fragments were obtained, low 
amounts of higher molecular weight adducts, probably dimers and trimers (ca. 95 and 135 kDa), were 
observed in the case of OVA extracted from NPs. Lanes 3 and 5 (blank NPs) show that no interference 
from the NP formulations is to be expected. 
In addition, ELISA was performed using the OVA which had been extracted from the NPs. By relating the 
result to the total amount of protein in the sample the activity of the encapsulated OVA was determined 
as 74% and 64% in PLGA and Chit.-PLGA NPs, respectively (results not shown).  
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Fig. 2:  Integrity of OVA extracted from NPs by 0.1 N NaOH and analyzed by SDS PAGE, Lane 1: 
MW standards, Lane 2: OVA control, Lane 3: Blank PLGA, Lane 4: OVA extracted from PLGA NPs, Lane 5: 
Blank Chit-PLGA, Lane 6: OVA extracted from Chit-PLGA NPs 
 
5.3.3. ACTIVATION OF DENDRITIC CELLS 
 
We analyzed the effect of PLGA-OVA and Chit.-PLGA-OVA on the activation and maturation of bone 
marrow-derived murine DCs. Both, PLGA-OVA and Chit.-PLGA-OVA were able to promote an efficient 
activation and maturation of DCs in vitro when used at a final OVA concentration of 10 µg/ml (Fig. 3). 
Changes in the activation markers (% of CD11c+ DCs indicates the number of activated DCs; mean 
fluorescence intensity (MFI) indicates the expression level of a certain marker per cell) were modest but 
except for CD54 an increase compared to negative control was detected for all NP groups as well as for 
OVA alone (Fig. 4). Interestingly, no significant differences in the expression levels of activation markers 
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have been observed comparing values of DCs stimulated with OVA alone with those of DCs incubated in 
the presence of any NP formulation (Fig. 4). In general incubation of DCs in the presence of OVA alone 
and in combination with LPS stimulated similar changes in activation markers except for CD40 and CD80 
where the addition of LPS increased the marker expression per cell (Fig. 4).  
However, we next evaluated the capacity of APCs loaded with antigen in presence of PLGA-OVA and 
Chit-PLGA-OVA to stimulate the proliferation of antigen-specific CD8+ and CD4+ T cells. DCs stimulated 
with OVA loaded Chit.-PLGA NPs were able to induce a strong antigen-specific proliferation of CD8+ T 
cells (67.5%) from OT-I mice, as shown by the loss of CFSE+ stained cells (Fig. 3, left column). 
Furthermore, theses DCs were also able to stimulate the proliferation of CD4+ T cells (95.6%) derived 
from OT-II mice (Fig. 3, right column). Nevertheless, weaker T cell proliferation was also observed when 
DCs were stimulated with OVA LPS-free alone (21 and 68%, for OT.I and OT-II respectively) (Fi.g 3). DCs 
stimulated with OVA loaded PLGA NPs were also able to stimulate the proliferation of OT-I and OT-II cells 
although to a lesser extend compared with OVA alone and the OVA loaded Chit.-PLGA NPs (10 and 95%, 
respectively) (Fig. 3). OVA free NPs promote only very marginal DC activation/ T-cell proliferation if any 
at all (Fig. 3). Interestingly, LPS induced only week CD4+ T cell proliferation compared to OVA and PLGA-
OVA and Chit.-PLGA-OVA (Fig. 3) 
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Fig. 3:  Ova-specific proliferation of OT-I (left panel) and OT-II lymphocytes (right panel) 
stimulated by NP-OVA pulsed DCs. Bone marrow-derived DCs were incubated for 24 h in the presence of 
OVA LPS free [10 µg/ml], PLGA, PLGA-OVA [10 µg/ml], Chit.-PLGA and Chit.-PLGA-OVA [10 µg/ml], 
respectively. Non-stimulated pulsed DCs were used as negative control. Then, the loaded DCs were co-
cultured with either CFSE labeled naïve CD8+ or CD4+ T cells derived from OT-I and OT-II mice, 
respectively, for 4 days and further analyzed by flow cytometry. The results are representative out of 
two experiments and are expressed as histograms showing the percentage of proliferating OVA-specific 
T cells of all CD8+ (OT-I) and CD4+ (OT-II) T cells, respectively. 
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Fig. 4:  Expression of activation marker by murine DCs after stimulation with PLGA-OVA and 
Chit.-PLGA-OVA. The expression of surface markers on CD11c+-gated bone marrow-derived murine DCs 
following stimulation with OVA LPS free [10 µg/ml], PLGA, PLGA-OVA [10 µg/ml], Chit.-PLGA and Chit.-
PLGA-OVA [10 µg/ml], respectively, was investigated by flow cytometry. After 24 h of incubation DCs 
were stained with Abs specific for CD40, CD54, CD80, CD86, MHC-I and MHC-II molecules and analyzed 
by flow cytometry (BD LSR-II). Results are mean ± SEM of three independent experiments and expressed 
as percentage (a) and mean fluorescence intensity (MFI) (b), respectively, of CD11c+ cells.  
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5.3.4. ADOPTIVE TRANSFER MODEL OF TCR TRANSGENIC CD4+ T CELLS TO 
CHARACTERIZE OVA SPECIFIC PROLIFERATION 
 
In order to verify the feasibility of transfollicular immunization as alternative vaccination strategy, an 
adoptive transfer model was established. Proliferation of adoptively transferred OVA specific CD4+ T 
cells was measured by CFSE dilution in the draining lymph nodes and secondary lymphatic organ.  
The number of divided OVA specific CD4+ T cells is shown in Fig. 5 (one representative animal of 4 
animals per group). As expected no proliferation of transferred cells isolated from draining lymph nodes 
have been observed in the negative control (Fig. 5a), whereas animals of group 2 (immunized i.m. with 
OVA protein as positive control) showed a strong proliferation (95.9% of the transferred cells 
proliferated for up to seven divisions, Fig. 5b). Mice immunized by transfollicular application of Chit.-
PLGA-OVA co-administered with c-di-AMP as adjuvant showed a comparable proliferation potential 
(96.2%) and divided up to nine times (Fig. 5c).  
Fig. 6 shows the percentage of divided transferred cells for each experimental group. The four animals of 
each group were analyzed separately. While no proliferation was observed in the negative control (group 
1), full proliferation of the transferred cells was observed in animals of the positive control group (group 
2) and in animals immunized transfollicularly with Chit.-PLGA-OVA and c-di-AMP as adjuvant (group 3). 
An adoptive transfer experiment demonstrated that the model antigen OVA can be delivered via the 
transfollicular route. This preliminary experiment is a proof of concept that by this transfollicular 
immunization approach it is possible to deliver antigens, thereby stimulating antigen-specific T cells. 
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Fig. 5:  Animals of group 1 were immunized with empty Chit-PLGA NPs and the adjuvant c-di-
AMP i.m. As expected no proliferation of transferred cells was observed in this negative control (A). 
Animals of group 2 were immunized i.m. with OVA protein as positive control. More than 95% of the 
transferred cells proliferated after this stimulation (B). The mice of group 3 were immunized by 
transfollicular application of OVA loaded Chit.-PLGA NPs and c-di-AMP as adjuvant which led to 
proliferation comparable to the positive control (C). Shown is the proliferation of cells isolated from 
draining lymph nodes of one representative animal per group. 
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Fig. 6:  The percentage of divided transferred cells in the draining lymph nodes (a) and the 
spleen (b) for each experimental group is shown. The four animals of each group were analyzed 
separately. While no proliferation was observed in the negative control (Gr. 1), full proliferation of the 
transferred cells was observed in animals of the positive control group (Gr. 2), and in animals immunized 
transfollicularly with Chit.-PLGA-OVA and c-di-AMP as adjuvant (Gr. 3). This experiment demonstrates 
that the model antigen OVA can be delivered via the transfollicular route and that the immunization by 
this route is able to elicit the same proliferation of OVA specific CD4+ T cells as the i.m. injection of OVA. 
 
5.3.5. FOLLICULAR UPTAKE OF NANOPARTICLES 
 
Fig. 7 shows representative images illustrating the distribution of fluorescently labeled NPs on the skin 
surface and in the hair follicle after application to excised pig ears. From both the cross-section as well as 
the top-view it is apparent that the NPs accumulated in the follicle openings, cover the hair and invade 
into the follicular duct (Fig. 7 (a,b)). Fig. 7c shows a cyanoacrylate biopsy of the follicular content, which 
further confirms the presence of NPs inside the hair follicles.  
By extracting cyanoacrylate biopsies with organic solvents and quantifying the fluorescence in the 
extract the uptake into the follicles was quantified (Fig. 8). Encapsulation of OVA into NPs significantly 
enhanced follicular uptake of OVA by a factor of 2.85 ± 0.6 (FITC-OVA in PLGA NPs) and 2.33 ± 0.52 (FITC-
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OVA in Chit.-PLGA NPs) compared to OVA solution (Fig. 7a). Follicular uptake of OVA was slightly lower 
for Chit.-PLGA compared to PLGA NPs, however, this difference was not significant (Fig. 8a).  
Furthermore, using FITC-labeled PLGA it turned out that follicular uptake of particles is a function of the 
NP dose/area relation. Thus the uptake can further be enhanced by increasing the NP concentration in 
the formulation (Fig. 8b). 
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Fig. 7:  Distribution of fluorescently labeled NPs in hair follicles after application to excised pig 
ears. (LSM 510 Meta, Carl Zeiss GmbH, Jena Germany; excitation wavelength 458 nm)  
(a) Top view onto the skin surface – image reconstituted after optical sectioning (41 individual frames of 
3 µm thickness): NPs accumulate in the follicle opening. The hair is visible as a negative image due to NPs 
on the hair surface. 
(b) Transversal cryo section (thickness 12 µm); overlay of fluorescence and transmission light images: 
NPs are visible on the skin surface and inside the follicle.  
(c) Cyanoacrylate biopsy – one plane selected from optical sectioning (section thickness 0.5 µm); the 
position of the plane relative to the entire optical stack can be estimated from the height of the box; 
overlay of fluorescence and transmission light images; the skin surface is oriented towards the bottom of 
the image: NPs are visible deep inside the cyanoacrylate biopsy which was performed to extract the 
follicular content. 
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Fig. 8:  (a) Uptake of FITC-labeled OVA encapsulated in NPs relative to FITC-OVA solution A: 
FITC-Ova solution, B: FITC-OVA in PLGA NPs, C: FITC-OVA in Chit.-PLGA NP. (applied dose: 8.5 µg 
OVA/cm², 0.42 mg NPs/cm²; n = 6, mean ± SEM; * indicates significant differences compared to A with p 
˂ 0.05) 
(b) Effect of NP concentration on follicular uptake. The results are expressed relatively to the lowest NP 
concentration. (n = 3 except for the highest conc. measured with Chit.-PLGA NPs where n = 2, mean ± 
SEM; * indicates significant differences compared to the lowest NP concentration with p ˂ 0.05) 
 
Non-invasive delivery of nanoparticles to hair follicles 
    70 
 
5.4. DISCUSSION 
 
Transfollicular delivery of antigen by using NPs holds the potential for TCI without the need to weaken 
the protective SC barrier. So far, studies demonstrating transfollicular antigen delivery used additional 
barrier disrupting methods such as tape stripping, plucking or intense skin hydration [15, 88, 89]. We 
hypothesize that by encapsulating the antigen into NPs transfollicular vaccination can be optimized, 
benefiting from the unique properties of such nano-formulations which should finally allow the 
application without any barrier disrupting measures. Most NPs cannot overcome the intact SC except for 
ultrafine particles (< 10 nm, consequently suffering from an extremely low loading capacity) and ultra-
flexible liposomes [79]. However, once the particles are located deep inside the hair follicles the SC is no 
longer an obstacle towards penetration. It has already been demonstrated (although only in mice) that 
200 nm particles can be taken up by perifollicular APCs [88, 89]. In fact, transfollicular vaccination by 
using NPs to encapsulate the vaccine antigen imitates the natural route of delivery observed for pollen 
allergens in patients suffering from atopic dermatitis. Pollen grains are micron-sized particles which 
accumulate in the follicle openings and release the allergen after getting into contact with sweat [13, 
90]. Also, upon depletion LCs quickly re-populate the epidermis within a period of 24 h, the primary 
source for LCs being the hair follicles [91, 92].  
In this study we prepared polymeric NPs from PLGA and/or chitosan. Both polymers are widely used for 
drug delivery purposes, especially for preparing depot formulations with a sustained bioavailability of 
protein and peptide drugs [93-95]. Chitosan and its derivatives are widely used as non-viral vectors for 
nucleotide based drugs as these are easily complexed by the positively charged polymer [96, 97]. Both 
polymers are “generally regarded as safe” (GRAS), biocompatible and biodegradable. Chitosan 
furthermore has mucoadhesive properties, facilitates permeation, and has intrinsic adjuvant properties 
[98, 99]. 
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Encapsulation into NPs can help to stabilize protein based antigen, modify the release, and improve 
uptake by APCs [100-102]. At the same time the NP preparation process itself threatens protein integrity 
and bioactivity due to exposure to organic solvents, interfacial tension, and high shear forces [103]. 
Liquid/liquid and solid/liquid interfaces occur during all steps of protein encapsulation, protein release 
and storage and may cause conformational changes and/or aggregation. Apart from losing therapeutic 
activity aggregates may cause unpredictable side effects and lead to immunogenicity or toxicity [95]. 
During storage these issues may be minimized by freeze-drying. However, upon reconstituting the 
lyophilisate and during drug release degradation of PLGA will create an acidic microenvironment which 
leads to acidic hydrolysis of protein antigens [104, 105]. For comparison, commercially available 
preparations of BSA usually contain 5-20% of covalent multimeric water soluble aggregates [106]. We 
could show that 74% and 64% of OVA released from PLGA and Chit-PLGA NPs respectively bind to a 
monoclonal antibody. This allows a conservative estimate of the activity of the released OVA as at least 
the epitope recognized by the primary antibody in the ELISA has to be intact. Our results show that 
despite the formation of aggregates during particle preparation the activity of OVA was largely retained. 
In other words, by applying a usual dose of 8.5 µl NP suspension per cm² (50 mg NPs/ml, 54.3 ± 0.047 
and 66.5 ± 0.044 µg OVA/mg NPs, 74% and 64% activity, for PLGA and Chit.-PLGA NPs respectively) an 
effective dose of 17 µg/cm² (PLGA) or 18 µg/cm² (Chit.-PLGA) of active OVA is administered considering 
the measured loading efficiency and activity of the encapsulated OVA. 
Using OVA loaded PLGA and Chit.-PLGA NPs for the stimulation of DCs demonstrated that these particles 
exhibit the capacity to activate murine DCs in vitro (Fig. 4). This is a critical step for the development of 
immune interventions based on NPs, since activation and maturation of DCs is recognized as a key event 
in the stimulation of adaptive immune responses [107]. Only marginal differences have been observed 
comparing the expression levels of activation markers by DCs stimulated with OVA alone and OVA 
loaded NPs (Fig. 4). Only the number of MHC class II molecules seems to be slightly increased on DCs 
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stimulated with Chit.-PLGA formulations compared to those stimulated with OVA alone. This may be due 
to the influence of regulatory T cells present in the OT splenocyte preparation which was used to for the 
co-culture with DCs [108].  
Interestingly, following co-incubation of bone marrow derived DCs with OVA and LPS only CD40 
expression was increased compared to DCs stimulated with OVA alone, whereas in case of all other 
investigated markers only marginal differences have been observed (Fig. 4). In addition, also the capacity 
of LPS stimulated DCs to promote T cell proliferation was marginal (Fig. 3). One possible explanation 
might be a contamination of the assay with IL-10 which was shown to inhibit the expression of TLR4 by 
DCs which subsequently prevents their activation by the TLR4 agonist LPS [109]. The source of IL-10 
could be bone marrow-derived macrophages which were left in the DC population prepared from murine 
bone marrow and which were shown to produce IL-10 by stimulation with LPS [110]. 
Nevertheless, DCs stimulated with OVA loaded NPs were able to stimulate a strongly enhanced clonal 
expansion of OVA-specific CD4+ OT-II cells compared to those stimulated with OVA protein alone. 
However, only Chit.-PLGA NPs were able to also promote an enhanced proliferation of OVA-specific 
CD8+ OT-I cells (Fig. 3). An obvious difference between PLGA and Chit.-PLGA NPs which both have similar 
size/shape/OVA loading/Ova stability is their opposing surface charge (Table 1). This leads to conclude 
that the positive particle charge, which generally improves cellular adhesion, internalization, and 
endosomal escape, may be a reason for the superiority of the Chit.-PLGA NPs to promote CD4+ and CD8+ 
proliferation [111]. A preferred stimulation of CD8+ T cells may further be expected upon transfollicular 
application [17, 88]. Antigen uptake by DCs and induction of DC maturation by Chitosan and PLGA NPs 
has been investigated by other groups as well but shows inconclusive results, unfortunately also 
concerning the absence [112] or presence of an effect of particle surface charge [113]. This indicates that 
in addition to the surface charge also the composition of the NPs may play a role [114, 115]. The 
composition (e.g. degree of substitution, chain length) of the biopolymer chitosan depends on the source 
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of manufacturer as well as varies from batch to batch which makes it difficult to compare between 
studies.  
The adoptive transfer model is a well-established tool to characterize T cell activation in vivo, since TCR-
transgenic mice are tolerogenic to their TCR specific antigen (reviewed in [116]). In the present study 
adoptive transfer experiments were performed to analyze the transfollicular vaccination route in 
comparison with the i.m. route in an in vivo setting. Transfollicular immunization and subsequent 
analysis of the triggered immune responses in the draining lymph nodes and secondary lymphatic organ 
four days after immunization appealed as the most suitable technique to assess proliferation of the 
transferred cells. Indeed, transfollicular administered OVA in Chit.-PLGA NPs + c-di-AMP as adjuvant 
elicited strong OT-II cell proliferation. The fact that more cell divisions were observed after transfollicular 
administration of Chit.-PLGA-OVA NPs compared to those observed following i.m. administration of OVA 
alone provides evidence that combination of OVA with NPs activated the OVA-specific cells more 
efficiently which resulted in enhanced proliferation. Future immunization studies with disease relevant 
antigens need to show whether a potent immune response can be elicited by transfollicular vaccination 
without the use of barrier disrupting methods. It should be kept in mind that secondary to 
permeabilizing the skin, tape stripping or other barrier disrupting methods activate the innate immune 
response and thus work as an unspecific adjuvant. This includes the secretion of the proinflammatory 
cytokines TNF-α, IL-1α, IL-1β, and GM-CSF by keratinocytes. TNF-α and IL-1β trigger the upregulation of 
the expression of a6 integrins, intercellular adhesion molecule 1 (ICAM.1), CD86 and MHC class II 
molecules which then promote the dissociation of LCs from keratinocytes, their subsequent maturation 
and migration, and improves the antigen-specific immune responses [22, 91, 117]. The use of immune-
stimulating molecules or adjuvants in the formulation is an alternative to further optimize the elicited 
immune responses. This may become important to overcome the tolerogenic potential of the 
perifollicular LCs and dermal DCs. Mattheolabakis et al. showed that TCI with OVA encapsulated in 
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poly(lactic acid) NPs was less immunogenic than soluble OVA, however by the addition of the adjuvant 
cholera toxin boosted the immunogenicity of the NP formulation over that of soluble antigen [118].  
While the immunological response towards vaccines is foremost evaluated in different mouse models, 
rodent skin is not appropriate for testing transdermal delivery and especially transfollicular penetration. 
Mouse SC has a different corneocyte architecture as well as lipid composition and arrangements, leading 
mouse skin to be more leaky and therefore an inappropriate surrogate for transdermal delivery in man 
[119]. With special regards to their hairs, mice have a higher follicular density than man while pig and 
man resemble each other more closely (mouse: >5000/cm², pig: ca. 22/cm², human ca. 25/cm² on the 
forearm) [120, 121]. Due to the limitations the mouse model represents, we also investigated the 
delivery of nano-encapsulated OVA to terminal follicles on the porcine ear. Pig skin is an appropriate 
substitute for human skin, pig ears are the gold standard model for investigating follicular penetration 
[82, 122]. The ear cartilage prevents tensile fibers from irreversibly closing the follicle openings which 
drastically reduces follicular uptake in excised human skin [123].  
For transfollicular vaccination it will be essential that the delivery efficiency into the hair follicle is high, 
i.e. that major parts of the dose are delivered to the peri-follicular APCs. We observed the distribution of 
the NPs on the skin surface and within the follicular duct (Fig. 5). The real invasion depth into the follicle 
remains elusive from these images as only the upper part of the follicle is visible in the cross-section. It 
requires an extensive number of consecutive cuts to obtain reliable measurements due to the angular 
orientation of the hairs inside the skin [11, 124]. We observed 2-3 times higher drug amounts in the hair 
follicles if OVA was encapsulated in NPs compared to solution. The follicular uptake efficiency could 
further be increased by increasing the NP dose/area. No significant differences were observed in the 
follicular uptake of PLGA and Chit-PLGA NPs (Fig. 7a). Both NPs have a similar size and size distribution 
but opposite surface charges. These results are in line with the study by Patzelt et al. who suggested that 
the invasion depth into the follicles depends foremost on NP size and less on particle surface properties 
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[11]. In general, follicular uptake of microparticles is preferred [125]. For terminal hairs in pigs the 
optimum particle size for deep penetration was found to be 650 nm [11, 124]. The data presented in this 
work further underline the great potential of NPs to improve transfollicular vaccination as compared to 
administering the “naked” antigen across the intact SC. 
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5.5. CONCLUSION 
 
In conclusion OVA protein could be incorporated with only moderate loss of biological activity into NPs 
made from PLGA and Chit-PLGA. Encapsulation increases the delivery of OVA to the follicle by a factor of 
2 to 3 and can be further increased by increasing the dose of particles applied by area. No pretreatment 
such as plucking the hairs, waxing or superglue stripping was required to achieve a follicular uptake so 
that the SC barrier was left intact. Deep penetration into the follicles by the help of NPs delivers the 
antigen into the vicinity of the perifollicular APCs. OVA loaded PLGA and Chit.-PLGA NPs were able to 
stimulate efficiently murine DCs and subsequently antigen-specific CD4+ and CD8+ T-cells. An adoptive 
transfer experiment demonstrated that the model antigen OVA can be delivered via the transfollicular 
route. This preliminary experiment is a proof of concept that by this transfollicular immunization 
approach it is possible to deliver antigens, thereby stimulating antigen-specific T cells. Thus, 
transfollicular delivery seems a promising opportunity vaccination strategy under critical hygienic 
conditions, for example in individuals with impaired immune system or the elderly. 
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SUMMARY 
Summary 
In this thesis the uptake of NPs into the HF was investigated with particular regard on quantity, to 
estimate the potential of NPs as drug carriers for transfollicular drug targeting, especially for 
transcutaneous vaccination.   
Based on the differential stripping technique a method was developed to quantify NP uptake into HF and 
applied in vitro in a pig ear model and in vivo in human volunteers. An excellent 
 in vitro-in vivo-correlation of r² = 0.987 between both models was demonstrated, supporting the 
suitability of the pig ear model as a surrogate for the in vivo situation in humans for quantifying NP 
uptake into HF.  
The influence of NP material on HF uptake was investigated using fluorescence labeled PLGA NP with 
different surface modifications: i) plain PLGA, ii) chitosan-coated PLGA, and iii) Chit.-PLGA coated with 
different PL (DPPC (100), DPPC : Chol (85:15), and DPPC : DOTAP (92:8)). The samples were extracted for 
fluorescence quantification in a mixture of ACN : NaOH. NPs coated with DPPC (100) and DPPC : DOTAP 
(92:8) penetrated into the HFs to a higher extent than the other tested nanoparticles. The effect was 
observed both in the pig ear model as well as in human volunteers. 
Only a small amount of topically applied NP penetrated into HFs, for transcutaneous vaccination it is 
essential to achieve the highest possible delivery efficiency. From literature it is known that NPs applied 
with massage penetrate deeper into the follicle compared to application without massage. Using the 
new quantification method it was investigated if application techniques like manual massage or vibration 
can enhance the amount of NPs delivered to the HF. Fluorescently labeled PLGA-NPs were applied on the 
pig ear model with i) without massage, ii) with manual massage with the gloved forefinger, iii) with a 
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vibrating massage device. However neither manual massage nor massage with a vibrating massage 
device were able to enhance the delivery efficacy significantly.  
Furthermore it was demonstrated that the usage of NP formulations instead of solutions enhances the 
deliver efficacy into the hair follicles. In the pig ear model the encapsulation in NP increased the follicular 
delivery of OVA by a factor of 2 – 3 compared to OVA solution. Increasing amount of NP applied onto 
skin may additionally increase the delivery efficiency by a factor of ~ 2 – 2.4. 
In a proof-of-concept study PLGA and Chit.-PLGA NPs were prepared with OVA as model antigen. OVA 
was successfully incorporated into the particles with only a moderate loss of biological activity. In a cell 
culture assay OVA loaded NPs stimulated the proliferation of CD4+ and CD8+ T-cells to a larger extent 
than OVA in solution. An adoptive transfer experiment in mice demonstrated the successful antigen 
delivery and immunization via the transfollicular route. With this preliminary experiment it was shown 
that transfollicular antigen delivery and immunization using nanoparticles as carrier system is possible. 
In summary transfollicular vaccination using NPs as vaccine carriers is a promising approach. The main 
challenge is to deliver a sufficient dose of antigen. Currently the major amount of applied antigen is lost 
on skin surface without being delivered to the immune system. Though promising results could be 
achieved the loss of antigen is not in line with dose sparing concepts. Future research should focus on 
the optimization of the carrier systems to enhance the targeting efficiency.  
The results of the proof of concept study in the mouse model were encouraging. Transfollicular 
vaccination studies in vivo should be expanded from the model antigen OVA in the mouse model to 
clinically used antigens like influenza vaccines and also be tested in different animal models. Due to the 
tremendous higher number of HF/cm² compared to human, the mouse model is only of limited 
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suitability. Encapsulating approved antigens in NPs made of FDA approved biodegradable and 
biocompatible polymers like PLGA even clinical trials in human could be feasible in the near future. 
The quantification method could help to develop carrier systems with enhanced penetration efficiency 
to the HF. The influence of the PL coatings was a first step to investigate uptake influencing parameters. 
Quantifying the penetration of NP into the hair follicles can be relevant for dose finding experiments not 
only for TCI but for follicular targeting in general. Using drug loaded carrier systems, the fate of the 
nanoparticles and the fate of the drug could be monitored simultaneously. The method can easily be 
modified with different analyzing methods like HPLC for example. Furthermore a combination with well-
established sampling techniques like tape stripping would be useful, especially if the hair follicle is used 
as target side. Already tape stripping is part of the sampling procedure with intention to clean the skin 
surface from remaining NP. Increasing the number of tape strips would allow performing a depth profile 
of the drug penetrated into the SC in parallel. Especially development and bioequivalence testing of 
therapeutics for hair follicle related disorders like acne or alopecia could benefit of this method.  
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ZUSAMMENFASSUNG 
Zusammenfassung 
In dieser Arbeit wurde die Aufnahme von Nanopartikeln in Haarfollikel untersucht, wobei das 
Hauptaugenmerk auf die Quantität der Aufnahme gelegt wurde. Hierdurch sollte die Eignung von 
polymerischen Nanopartikeln als Arzneistoffträger für die transfollikuläre Anwendung, besonders die 
transfollikuläre Vakzinierung ermittelt werden.  
Basierend auf der Methode des differenzierten Strippings wurde eine Methode entwickelt um die 
Aufnahme topisch applizierter Nanopartikel in die Haarfollikel quantitativ zu bestimmen. Diese Methode 
wurde erfolgreich im Schweineohr-Modell in vitro und am Menschen in vivo angewandt, wobei eine 
hervorragende in-vitro-in-vivo-Korrelation von r² = 0.987 zwischen den beiden Modellen ermittelt 
wurde. Die Eignung des Schweineohr-Modells als Surrogat für die in vivo Situation am Menschen konnte 
somit auch für quantitative Untersuchungen am Haarfollikel belegt werden.   
Der Einfluss des Materials der Nanopartikel auf die Aufnahme in Haarfollikel wurde mit Hilfe 
fluoreszenzmarkierter Nanopartikel auf der Basis von PLGA untersucht, die mit unterschiedlichen 
Oberflächenmodifikationen versehen waren: i) unmodifiziertes PLGA, ii) mit Chitosan überzogenes PLGA 
(Chit.-PLGA) und iii) Chit.-PLGA mit Überzügen aus verschiedenen Phospholipiden (PL) (DPPC (100), 
DPPC:Chol. (85:15) und DPPC:DOTAP (92:8)). Die Proben wurden in einer Mischung aus ACN:NaOH 
extrahiert und anhand der Fluoreszenz quantitativ bestimmt. Als Effekt des Überzugs mit Phospholipiden 
drangen DPPC (100) und DPPC:DOTAP (92:8) stärker in die Haarfollikel ein als die übrigen getesteten 
Nanopartikel. Dieser Effekt wurde sowohl beim Schweineohr-Modell als auch bei den menschlichen 
Probanden beobachtet.  
Da nur ein kleiner Teil, der auf die Haut aufgetragenen Nanopartikel in die Haarfollikel eindringt ist es für 
die transkutane Vakzinierung essentiell, die größtmögliche Wirkstoffmenge im Follikel zu erreichen. Aus 
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der Literatur ist bekannt, dass Nanopartikel, die mit Massage aufgetragen wurden tiefer in die Follikel 
eindringen verglichen mit einer Applikation ohne Massage. Unter Anwendung der neuen 
Quantifikationsmethode wurde untersucht, ob Applikationstechniken wie manuelle Massage oder 
Vibration die in den Haarfollikel aufgenommene Menge an Nanopartikeln steigern können. 
Fluoreszenzmarkierte PLGA Nanopartikel wurden mit folgenden Techniken auf das Schweineohr-Modell 
aufgetragen: i) ohne Massage, ii) mit manueller Massage mit dem behandschuhten Zeigefinger, iii) mit 
einem vibrierenden Massagegerät. Weder die manuelle Massage noch Massage mit einem vibrierenden 
Massagegerät waren in der Lage, die Menge an Nanopartikeln im Haarfollikel signifikant zu steigern.  
Weiterhin konnte gezeigt werden, dass die Verwendung von Nanopartikeln als Arzneistoffträger, 
verglichen mit Lösungen die Wirkstoffmenge im Haarfollikel steigert. Im Schweineohr-Modell war die 
Menge an Ovalbumin im Haarfollikel 2 – 3-mal so hoch als bei der Verwendung einer Ovalbumin-Lösung.  
Zusätzlich kann die im Haarfollikel deponierte Wirkstoffmenge durch Auftragung größerer Mengen an 
Nanopartikeln um etwa den Faktor 2 – 2.4 gesteigert werden.  
Für eine Machbarkeitsstudie wurden PLGA und Chitosan-PLGA Nanopartikel mit Ovalbumin als 
Modellantigen hergestellt. Ovalbumin wurde erfolgreich, mit nur einem moderaten Verlust an 
biologischer Aktivität in die Partikel eingearbeitet. In einer Zellkulturuntersuchung stimulierte das 
eingeschlossene Ovalbumin die Proliferation von CD4+  und CD8+-T-Zellen  stärker als Ovalbumin-
Lösung. Im adoptiven Zelltransfer wurde gezeigt, dass das Modellantigen Ovalbumin über die 
transfollikuläre Route appliziert werden kann. Dieses erste Experiment ist ein Machbarkeitsnachweis für 
die Applikation von Antigenen und gleichzeitige Stimulation Antigen spezifischer T-Zellen durch 
transfollikuläre Vakzinierung durch Nanopartikel als Trägersystem.  
Zusammenfassend kann man die transfollikuläre Vakzinierung mit Nanopartikeln als Impfstoffträger als 
vielversprechenden Ansatz bezeichnen. Die größte Herausforderung besteht jedoch darin, eine 
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ausreichend große Menge an Antigen verabreichen zu können. Bislang geht der größte Teil des 
aufgetragenen Antigens auf der Hautoberfläche verloren. Obgleich erste Ergebnisse vielversprechend 
waren lässt sich dies nicht mit Konzepten zur Dosiseinsparung vereinbaren. Die weitere Forschung sollte 
sich darum auf die Optimierung von Trägersystemen konzentrieren um die Wirkstoffmenge im 
Haarfollikel steigern zu können.  
Die Ergebnisse der Machbarkeitsstudie am Mausmodell waren vielversprechend. In vivo-Studien zur 
transfollikulären Vakzinierung sollten vom Modellantigen Ovalbumin zu klinisch genutzten Antigenen wie 
Grippeimpfstoffen ausgeweitet werden und auch in anderen Tiermodellen durchgeführt werden. 
Aufgrund der extrem höheren Haarfollikeldichte der Maus im Vergleich zum Menschen, ist das 
Mausmodell nur bedingt geeignet. Werden zugelassene Impfstoffe in Nanopartikel aus von der FDA 
zugelassenen Polymeren eingearbeitet wäre sogar die Durchführung von klinischen Studien am 
Menschen in naher Zukunft denkbar.  
Die Quantifikationsmethode kann bei der Entwicklung von Trägersystemen mit gesteigertem 
Penetrationsvermögen in die Haarfollikel helfen. Die Untersuchung des Einflusses von Phospholipid-
Überzügen war ein erster Schritt, die Aufnahme beeinflussende Parameter zu ermitteln. Die quantitative 
Bestimmung der aufgenommenen Menge an Nanopartikeln im Haarfollikel ist relevant zur 
Dosisbestimmung, nicht nur für transkutane Immunisierung sondern für den Haarfollikel betreffende 
Therapie im Allgemeinen. Werden arzneistoffbeladene Nanopartikel verwendet, können der Verbleib der 
Partikel und der des Arzneistoffs parallel bestimmt werden. Die Methode kann einfach mit etablierten 
Untersuchungsmethoden wie beispielsweise der Tape-stripping-Technik kombiniert werden. Dies ist vor 
allem dann von Interesse, wenn die Haarfollikel die eigentlichen Therapieziele sind. Tape-stripping ist 
bereits jetzt Bestandteil des Probenzugs und wird eingesetzt, um die Hautoberfläche von dort 
verbliebenen Nanopartikeln zu reinigen. Durch eine größere Anzahl durchgeführter Tesafilmabrisse 
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könnte so simultan zur Bestimmung der Penetration in die Haarfollikel ein Tiefenprofil von in das 
Stratum corneum eingedrungenem Arzneistoff erstellt werden. Vor allem die Entwicklung aber auch 
Bioequivalenzstudien von Therapeutika gegen Erkrankungen, die die Haarfollikel betreffen, wie 
beispielsweise Akne oder Haarausfall, können von dieser Methode profitieren.  
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ABBREVIATIONS 
Abbreviations 
ACN   Acetonitrile 
APC   Antigen presenting cell 
BSA   Bovine serum albumin 
cART   Combination antiretroviral therapie 
CD 4/ CD 8  Clusters of differentiation (4 or 8) 
CFSE   Carboxyfluoresceine succinimidyl ester 
Chit-PLGA  Chitosan-PLGA 
Chol.   Cholesterol 
dd   double distilled 
DC   Dendritic cell 
DNA   Deoxyribonucleic acid 
DPPC   Dipalmitoylphosphatidylcholine 
DOTAP   1,2-Dioleoyl-3-trimethylammonium-propan 
ELISA   Enzyme linked immuno assay 
ESEM   Environmental scanning electron microscopy 
FACS   Fluorescence activated cell sorting 
FITC   Fluorescein isothiocynate 
GRAS   Generally regarded as safe 
HIV   Human immunodeficiency virus 
HPLC UV/MS  high performance liquid chromatography  ultraviolet/ mass spectroscopy 
IQR   Interquartile range 
ivivc   in vitro in vivo correlation 
LC   Langerhans cell 
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LLOD   Lower limit of detection 
LLOQ   Lower limit of quantification 
LPS   Lipopolysaccharide 
LSM   laser scanning microscopy 
LT   E. coli heat labile toxine 
MFI   Mean fluorescence intensity 
MHC  Major Histocompatibility Complex 
MP   Microparticle 
NaOH   Sodium hydroxide 
NP   Nanoparticle 
OECD   Organisation for Economic Co-operation and Development 
OVA   Ovalbumin 
PBS   Phosphate buffer saline 
PDI   Polydispersity index 
PLGA   Poly lactide-co-glcolide 
PVA   Polyvinyl alcohol 
ROI   Region of interest  
SC   Stratum corneum 
SCCNFP  Scientific Committee on Cosmetic Products and Non-food products 
SD   Standard deviation 
SDS PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Scanning electron microscopy 
SEM   Standard error mean 
TCI   Transcutaneous Immunization 
TCR   T-cell receptor 
TEM   Transmission electron microscopy 
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TEWL   Transepidermal water loss 
WHO   World Health Organization 
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